VolitionRx Limited (VNRX) 10-Q 14 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Nov. 06, 2024
Cover [Abstract]
Entity Registrant Name	VOLITIONRX LIMITED
Entity Central Index Key	0000093314
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2024
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Entity Common Stock Shares Outstanding		92,664,812
Entity File Number	001-36833
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	91-1949078
Entity Address Address Line 1	1489 West Warm Springs Road
Entity Address Address Line 2	Suite 110
Entity Address City Or Town	Henderson
Entity Address State Or Province	NV
Entity Address Postal Zip Code	89014
City Area Code	646
Local Phone Number	650–1351
Security 12b Title	Common Stock, par value $0.001 per share
Trading Symbol	VNRX
Security Exchange Name	NYSE
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 5,414,146	$ 20,729,983
Accounts receivable	312,611	242,617
Prepaid expenses	689,995	521,370
Other current assets	384,189	360,125
Total Current Assets	6,800,941	21,854,095
Property and equipment, net	4,908,148	5,523,013
Operating lease right-of-use assets	635,857	549,504
Intangible assets, net	335,309	23,886
Total Assets	12,680,255	27,950,498
Current Liabilities
Accounts payable	2,485,077	3,211,287
Accrued liabilities	3,480,207	3,928,761
Deferred revenue	22,893,400	23,000,000
Management and directors' fees payable	24,851	59,625
Current portion of long-term debt	965,021	1,207,007
Current portion of finance lease liabilities	49,990	48,570
Current portion of operating lease liabilities	219,060	199,323
Current portion of grant repayable	65,646	55,855
Warrant liability	96,225	126,649
Total Current Liabilities	30,279,477	31,837,077
Long-term debt, net of current portion	3,837,950	3,624,860
Finance lease liabilities, net of current portion	366,175	400,022
Operating lease liabilities, net of current portion	448,045	378,054
Grant repayable, net of current portion	388,898	422,707
Total Long-Term Liabilities	5,041,068	4,825,643
Total Liabilities	35,320,545	36,662,720
Stockholders' Deficit
Common Stock Authorized: 175,000,000 shares of common stock, at $0.001 par value per shareIssued and outstanding: 92,392,570 shares and 81,898,321 shares, respectively	92,393	81,898
Additional paid-in capital	202,014,277	194,448,414
Accumulated other comprehensive income	140,272	243,940
Accumulated deficit	(223,750,970)	(202,576,507)
Total VolitionRx limited Stockholders' Deficit	(21,504,028)	(7,802,255)
Non-controlling interest	(1,136,262)	(909,967)
Total Stockholders' Deficit	(22,640,290)	(8,712,222)
Total Liabilities and Stockholders' Deficit	$ 12,680,255	$ 27,950,498

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets(Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Condensed Consolidated Balance Sheets
Common Stock, Shares Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	175,000,000	175,000,000
Common Stock, Shares Issued	92,392,570	81,898,321
Common Stock, Shares Outstanding	92,392,570	81,898,321

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues
Services	$ 68,434	$ 37,688	$ 155,713	$ 93,207
Product	406,088	127,523	886,141	438,122
Total Revenues	474,522	165,211	1,041,854	531,329
Operating Expenses
Research and development	3,473,782	4,650,658	11,819,106	15,007,623
General and administrative	1,815,863	2,599,908	6,353,647	7,826,568
Sales and marketing	1,053,584	1,567,700	4,112,731	4,944,259
Total Operating Expenses	6,343,229	8,818,266	22,285,484	27,778,450
Operating Loss	(5,868,707)	(8,653,055)	(21,243,630)	(27,247,121)
Other Income (Expenses)
Grant income	85,378	48,656	85,378	214,451
Loss on disposal of fixed assets	(1,195)	(15,913)	(34,693)	(15,913)
Interest income	530	230	9,634	84,987
Interest expense	(89,456)	(53,980)	(247,871)	(163,623)
Gain on change in fair value of warrant liability	4,872	220,874	30,424	249,845
Total Other Income (Expenses)	129	199,867	(157,128)	369,747
Net Loss	(5,868,578)	(8,453,188)	(21,400,758)	(26,877,374)
Net Loss Attributable to Non-Controlling Interest	47,049	82,887	226,295	256,546
Net Loss Attributable to VolitionRx Limited Stockholders	(5,821,529)	(8,370,301)	(21,174,463)	(26,620,828)
Other Comprehensive Income (Loss)
Foreign currency translation adjustments	(141,980)	31,291	(103,668)	12,525
Net Comprehensive Loss	$ (6,010,558)	$ (8,421,897)	$ (21,504,426)	$ (26,864,849)
Net Loss Per Share - Basic and Diluted Attributable to VolitionRx Limited	$ (0.07)	$ (0.11)	$ (0.25)	$ (0.39)
Weighted Average Shares Outstanding- Basic and Diluted	$ 87,886,012	$ 78,176,859	$ 84,165,579	$ 68,494,766

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders Equity (Unaudited) - USD ($)	Total	Common stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Noncontrolling Interest
Balance, shares at Dec. 31, 2022		57,873,379
Balance, amount at Dec. 31, 2022	$ (3,126,962)	$ 57,873	$ 164,397,468	$ 227,097	$ (167,257,429)	$ (551,971)
Common stock issued for cash, net of issuance costs, shares		5,225,703
Common stock issued for cash, net of issuance costs, amount	8,427,655	$ 5,225	8,422,430	0	0	0
Common stock issued for settlement of RSUs, shares		26,978
Common stock issued for settlement of RSUs, amount	0	$ 27	(27)	0	0	0
Stock-based compensation	693,657	0	693,657	0	0	0
Tax withholdings paid related to stock-based compensation	(14,336)	$ 0	(14,336)	0	0	0
Common stock repurchased, shares		(13,294)
Common stock repurchased, amount	(31,772)	$ (13)	(31,759)	0	0	0
Foreign currency translation	(56,478)	0	0	(56,478)	0	0
Net loss for the period	(8,872,909)	$ 0	0	0	(8,779,548)	(93,361)
Balance, shares at Mar. 31, 2023		63,112,766
Balance, amount at Mar. 31, 2023	(2,981,145)	$ 63,112	173,467,433	170,619	(176,036,977)	(645,332)
Balance, shares at Dec. 31, 2022		57,873,379
Balance, amount at Dec. 31, 2022	(3,126,962)	$ 57,873	164,397,468	227,097	(167,257,429)	(551,971)
Balance, shares at Sep. 30, 2023		78,343,417
Balance, amount at Sep. 30, 2023	(2,851,309)	$ 78,343	191,517,500	239,622	(193,878,257)	(808,517)
Balance, shares at Mar. 31, 2023		63,112,766
Balance, amount at Mar. 31, 2023	(2,981,145)	$ 63,112	173,467,433	170,619	(176,036,977)	(645,332)
Common stock issued for cash, net of issuance costs, shares		14,950,000
Common stock issued for cash, net of issuance costs, amount	17,086,606	$ 14,950	17,071,656	0	0	0
Common stock issued for settlement of RSUs, shares		74,598
Common stock issued for settlement of RSUs, amount	0	$ 75	(75)	0	0	0
Stock-based compensation	592,174	0	592,174	0	0	0
Tax withholdings paid related to stock-based compensation	(65,895)	0	(65,895)	0	0	0
Foreign currency translation	37,712	0	0	37,712	0	0
Net loss for the period	(9,551,277)	$ 0	0	0	(9,470,979)	(80,298)
Balance, shares at Jun. 30, 2023		78,137,364
Balance, amount at Jun. 30, 2023	5,118,175	$ 78,137	191,065,293	208,331	(185,507,956)	(725,630)
Common stock issued for cash, net of issuance costs, amount	(12,501)	$ 0	(12,501)	0	0	0
Common stock issued for settlement of RSUs, shares		206,053
Common stock issued for settlement of RSUs, amount	0	$ 206	(206)	0	0	0
Stock-based compensation	537,980	0	537,980	0	0	0
Tax withholdings paid related to stock-based compensation	(73,066)	0	(73,066)	0	0	0
Foreign currency translation	31,291	0	0	31,291	0	0
Net loss for the period	(8,453,188)	$ 0	0	0	(8,370,301)	(82,887)
Balance, shares at Sep. 30, 2023		78,343,417
Balance, amount at Sep. 30, 2023	(2,851,309)	$ 78,343	191,517,500	239,622	(193,878,257)	(808,517)
Balance, shares at Dec. 31, 2023		81,898,321
Balance, amount at Dec. 31, 2023	(8,712,222)	$ 81,898	194,448,414	243,940	(202,576,507)	(909,967)
Common stock issued for cash, net of issuance costs, shares		13,350
Common stock issued for cash, net of issuance costs, amount	15,734	$ 13	15,721	0	0	0
Common stock issued for settlement of RSUs, shares		68,169
Common stock issued for settlement of RSUs, amount	0	$ 69	(69)	0	0	0
Stock-based compensation	411,220	0	411,220	0	0	0
Tax withholdings paid related to stock-based compensation	(3,062)	0	(3,062)	0	0	0
Foreign currency translation	15,026	0	0	15,026	0	0
Net loss for the period	(8,472,005)	$ 0	0	0	(8,367,388)	(104,617)
Common stock issued in lieu of license fee, shares		129,132
Common stock issued in lieu of license fee, amount	125,258	$ 129	125,129	0	0	0
Balance, shares at Mar. 31, 2024		82,108,972
Balance, amount at Mar. 31, 2024	(16,620,051)	$ 82,109	194,997,353	258,966	(210,943,895)	(1,014,584)
Balance, shares at Dec. 31, 2023		81,898,321
Balance, amount at Dec. 31, 2023	(8,712,222)	$ 81,898	194,448,414	243,940	(202,576,507)	(909,967)
Balance, shares at Sep. 30, 2024		92,392,570
Balance, amount at Sep. 30, 2024	(22,640,290)	$ 92,393	202,014,277	140,272	(223,750,970)	(1,136,262)
Balance, shares at Mar. 31, 2024		82,108,972
Balance, amount at Mar. 31, 2024	(16,620,051)	$ 82,109	194,997,353	258,966	(210,943,895)	(1,014,584)
Common stock issued for cash, net of issuance costs, shares		734,155
Common stock issued for cash, net of issuance costs, amount	589,488	$ 734	588,754	0	0	0
Common stock issued for settlement of RSUs, shares		85,187
Common stock issued for settlement of RSUs, amount	0	$ 85	(85)	0	0	0
Stock-based compensation	208,046	0	208,046	0	0	0
Tax withholdings paid related to stock-based compensation	(38,205)	0	(38,205)	0	0	0
Foreign currency translation	23,286	0	0	23,286	0	0
Net loss for the period	(7,060,175)	$ 0	0	0	(6,985,546)	(74,629)
Balance, shares at Jun. 30, 2024		82,928,314
Balance, amount at Jun. 30, 2024	(22,897,611)	$ 82,928	195,755,863	282,252	(217,929,441)	(1,089,213)
Common stock issued for cash, net of issuance costs, shares		9,170,000
Common stock issued for cash, net of issuance costs, amount	5,960,200	$ 9,170	5,951,030	0	0	0
Common stock issued for settlement of RSUs, shares		294,256
Common stock issued for settlement of RSUs, amount	0	$ 295	(295)	0	0	0
Stock-based compensation	323,539	0	323,539	0	0	0
Tax withholdings paid related to stock-based compensation	(15,860)	0	(15,860)	0	0	0
Foreign currency translation	(141,980)	0		(141,980)	0	0
Net loss for the period	(5,868,578)	$ 0	0		(5,821,529)	(47,049)
Balance, shares at Sep. 30, 2024		92,392,570
Balance, amount at Sep. 30, 2024	$ (22,640,290)	$ 92,393	$ 202,014,277	$ 140,272	$ (223,750,970)	$ (1,136,262)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating Activities
Net loss	$ (21,400,758)	$ (26,877,374)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	817,542	855,947
Amortization of operating lease right-of-use assets	169,273	194,036
Loss on disposal of fixed assets	34,693	15,913
Stock-based compensation	942,805	1,823,811
Gain on change in fair value of warrant liability	(30,424)	(249,845)
Changes in operating assets and liabilities:
Prepaid expenses	(168,625)	(2,402)
Accounts receivable	(69,992)	(34,441)
Other current assets	(24,064)	(45,785)
Deferred revenue, current and non-current	(106,600)	0
Accounts payable and accrued liabilities	(416,167)	12,128
Management and directors' fees payable	(34,774)	(11,137)
Right-of-use assets operating leases liabilities	(174,758)	(191,586)
Net Cash Used In Operating Activities	(20,461,849)	(24,510,735)
Investing Activities
Purchases of property and equipment	(204,898)	(775,027)
Purchase of License	(171,095)	0
Net Cash Used In Investing Activities	(375,993)	(775,027)
Financing Activities
Net proceeds from issuances of common stock	6,565,422	25,795,654
Tax withholdings paid related to stock-based compensation	(57,127)	(80,231)
Common stock repurchased	0	(31,772)
Proceeds from grants repayable	0	27,052
Proceeds from long-term debt	754,457	216,908
Payments on long-term debt	(831,542)	(680,325)
Payments on grants repayable	(28,213)	0
Payments on finance lease obligations	(35,621)	(35,071)
Net Cash Provided By Financing Activities	6,367,376	25,212,215
Effect of foreign exchange on cash	(845,371)	15,244
Net change in cash and cash equivalents	(15,315,837)	(58,303)
Cash and cash equivalents - beginning of the period	20,729,983	10,867,050
Cash and cash equivalents - End of Period	5,414,146	10,808,747
Supplemental Disclosures of Cash Flow Information
Interest paid	247,871	163,623
Non-Cash Financing Activities
Common stock issued upon cashless exercises of stock options and settlement of vested RSUs	578	308
Offering costs from issuance of common stock	245,107	239,772
Fair value of warrants issued in connection with public offering	0	366,960
Common stock issued for License rights	125,258	0
Non-cash note payable	$ 294,603	$ 356,258

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Summary of Significant Accounting Policies	Note 1 – Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and use of estimates The accompanying unaudited condensed consolidated financial statements of VolitionRx Limited (the “Company” or “VolitionRx”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q of Regulation S-X. They do not include all the information and footnotes required by GAAP for complete financial statements. The December 31, 2023 consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the audited consolidated financial statements and accompanying notes thereto for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 25, 2024 (the “Annual Report”). The interim unaudited condensed consolidated financial statements should be read in conjunction with those audited consolidated financial statements included in the Annual Report. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The preparation of the Company's Condensed Consolidated Financial Statements requires management to make certain estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported and reported amounts of revenues and expenses. Such estimates include impairment of long-lived assets, accounts receivable, useful lives of intangible assets and property and equipment, fair values of stock-based awards, income taxes among others. These estimates and assumptions are based on management’s judgment. Estimates and underlying assumptions are reviewed on an ongoing basis. Changes in accounting estimates may be necessary if there are changes in the circumstances or experiences on which the estimate was based or as a result of new information. Changes in estimates, including those resulting from changes in the economic environment, are reflected in the period in which the change in estimate occurs. Reclassifications Certain reclassifications within operating expenses have been made to the prior period’s financial statements to conform to the current period financial statement presentation. There is no impact in total to the results of operations and cash flows in all periods presented. Recently Issued Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (the “FASB” issued Accounting Standards Update (“ASU”) 2023-07, “ Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, “ Income Taxes (Topic 740): Improvements to Income Tax Disclosures The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to its condensed consolidated financial statements. Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (continued) Fair Value Measurements Pursuant to ASC 820, “ Fair Value Measurements and Disclosures,” Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The financial instruments of the Company consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, debt, and a warrant liability. These items are considered Level 1 due to their short-term nature and their market interest rates, except for the warrant liability, which is considered Level 2 and is recorded at fair value at the end of each reporting period. Included in the following table are the Company’s major categories of assets and liabilities measured at fair value on a recurring basis as of September 30, 2024. Fair Value Measurements at September 30, 2024 Description Level 1 Level 2 Level 3 Total $ $ $ $ Liabilities Warrant liability - 96,225 - 96,225 As of December 31, 2023, the warrant liability was $126,649. The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis for the nine months ended September 30, 2024. Warrant Liability Total $ Balance at December 31, 2023 126,649 Gain on change in fair value of warrant liability (30,424 ) Balance at September 30, 2024 96,225 Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, “ Earnings Per Share,”

Liquidity and Going Concern Ass

Liquidity and Going Concern Assessment	9 Months Ended
	Sep. 30, 2024
Liquidity and Going Concern Assessment
Liquidity and Going Concern Assessment	Note 2 – Liquidity and Going Concern Assessment The Company's condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. Management assesses liquidity and going concern uncertainty in the Company’s consolidated financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued, which is referred to as the “look-forward period,” as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management considered various scenarios, forecasts, projections, estimates and made certain key assumptions, including the timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. For the nine months ended September 30, 2024, the Company incurred a net loss of $21.4 million and used cash flows in operating activities of $20.5 million. As of September 30, 2024, the Company had cash and cash equivalents of $5.4 million and an accumulated deficit of $223.8 million. The Company has generated operating losses and has experienced negative cash flows from operations since inception. The Company has not generated significant revenues and expects to incur further losses in the future, particularly from continued development of its clinical-stage diagnostic tests and commercialization activities. The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions or, financing, and/or generate revenues as may be required to sustain its operations. Management plans to address the above as needed by, (a) granting licenses and/or distribution rights to third parties in exchange for specified up-front and/or back-end payments, (b) obtaining additional financing through debt or equity transactions, (c) securing additional grant funds, and (d) developing and commercializing its products in an efficient manner. Management continues to exercise tight cost controls to conserve cash. As part of the Company’s cash conservation efforts, directors and certain employees have elected to exchange a portion of their fees earned or paid in cash or salary, respectively, for RSUs in the Company for a period of up to six months. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and to eventually attain profitable operations. Management assessed the mitigating effect of these plans to determine if it is probable that the plans would be effectively implemented within one year after the condensed consolidated financial statements are issued and when implemented, would mitigate the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern. These plans are subject to market conditions and reliance on third parties, and there is no assurance that effective implementation of the Company’s plans will result in the necessary funding to continue current operations and satisfy current and expected debt obligations. The Company has implemented short-term cash preservation and cost-saving initiatives to conserve cash. The Company concluded that these plans do not alleviate the substantial doubt about the Company’s ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2024
Property and Equipment
Property And Equipment	Note 3 - Property and Equipment The Company’s property and equipment consisted of the following amounts as of September 30, 2024 and December 31, 2023: September 30, 2024 December 31, 2023 Useful Life Cost $ Cost $ Computer hardware and software 3 years 751,488 724,534 Laboratory equipment 5 years 4,847,622 4,753,253 Office furniture and equipment 5 years 382,970 378,800 Buildings 30 years 2,132,927 2,113,031 Building improvements 5-15 years 1,690,268 1,610,016 Land Not amortized 133,715 132,468 Total property and equipment 9,938,990 9,712,102 Less accumulated depreciation 5,030,842 4,189,089 Total property and equipment, net 4,908,148 5,523,013 During the nine-month periods ended September 30, 2024 and September 30, 2023, the Company recognized $815,824 and $792,232, respectively, in depreciation expense.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2024
Intangible Assets
Intangible Assets	Note 4 - Intangible Assets The Company’s intangible assets consist of patents, mainly acquired in the acquisition of Belgian Volition. The patents are being amortized over the assets’ estimated useful lives, which range from 8 to 20 years. September 30, 2024 December 31, 2023 Cost $ Cost $ Patents 1,148,969 1,130,936 Licenses 296,353 - Total Patents and Licenses 1,445,322 1,130,936 Less accumulated amortization 1,110,013 1,107,050 Total patents and Licenses, net 335,309 23,886 During the nine-month periods ended September 30, 2024 and September 30, 2023, the Company recognized $(6,742) and $63,715, respectively, in amortization expense. The Company amortizes the patents and licenses on a straight-line basis with terms ranging from 8 to 20 years. The annual estimated amortization schedule over the next five years is as follows: 2024 $ 5,187 2025 $ 20,748 2026 $ 20,748 2027 $ 20,748 2028 $ 20,748 Greater than 5 years $ 247,130 Total Intangible Assets $ 335,309 The Company periodically reviews its long-lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360, “ Property, Plant and Equipment,

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2024
Related Party Transactions
Related-Party Transactions	No te 5 - Related-Party Transactions See Note 6, Common Stock Stock-Based Compensation,

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2024
Common Stock
Common Stock	Note 6 - Common Stock As of September 30, 2024, the Company was authorized to issue 175 million shares of common stock, par value $0.001 per share, of which 92,392,570 and 81,898,321 shares were issued and outstanding as of September 30, 2024 and December 31, 2023, respectively. Stock Option Exercises During the nine months ended September 30, 2024, no shares of common stock were issued pursuant to the exercise of stock options. Stock Options Expired / Cancelled On April 16, 2024, 36,821 vested stock options previously granted to an employee were cancelled and returned as authorized shares under the 2015 Stock Incentive Plan (the “2015 Plan”) on the expiration of the exercise period following the resignation of such employee. RSU Settlements Below is a table summarizing the RSUs that vested and settled during the nine months ended September 30, 2024, all of which were issued pursuant to the 2015 Plan. Equity Incentive Plan RSUs Vested (#) Vest Date Shares Issued (#) Shares Withheld for Taxes (#) 2015 21,582 Feb 8, 2024 21,582 - 2015 9,000 Mar 1, 2024 6,057 2,943 2015 44,217 Mar 27, 2024 40,530 3,687 2015 51,000 Apr 4, 2024 32,337 18,663 2015 50,000 May 1, 2024 34,496 15,504 2015 11,500 Jun 1, 2024 6,670 4,830 2015 14,962 Jun 15, 2024 11,684 3,278 2015 4,667 Jul 13, 2024 3,165 1,502 2015 29,000 Aug 15, 2024 21,291 7,709 2015 2,000 Sep 11, 2024 2,000 - 2015 2,500 Sep 21, 2024 2,500 - 2015 332,775 Sep 28, 2024 265,300 67,475 573,203 447,612 125,591 2023 Equity Capital Raise In connection with the June 2023 underwritten public offering of the Company’s common stock under the Company’s Registration Statement on Form S-3 (File No. 333-259783) effective November 8, 2021 (the “2021 Form S-3”), and pursuant to the underwriting agreement with Prime Executions, Inc, doing business as Freedom Capital Markets (“Freedom”), dated June 1, 2023, (the “2023” Equity Capital Raise”) the Company issued as compensation to Freedom warrants to purchase an aggregate of 448,500 shares of Company common stock at an exercise price of $2.00 per share. The Company evaluated the warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in ASC 480 and ASC 815-40. The Company determined the warrants issued to Freedom failed the indexation guidance under ASC 815-40, specifically, the warrants provide for a Black-Scholes value calculation in the event of certain transactions, which includes a floor on volatility utilized in the value calculation at 100% or greater. The Company has determined that this provision introduces leverage to the holders of the warrants that could result in a value that would be greater than the settlement amount of a fixed-for-fixed option on the Company’s own equity shares. Accordingly, pursuant to ASC 815-40, the Company has classified the fair value of the warrants as a liability upon issuance and marked to market each reporting period in the Company’s consolidated statement of operations until their exercise or expiration. The fair value of the warrants issued in the 2023 Equity Capital Raise as of September 30, 2024, and December 31, 2023, were $96,225 and $126,649 respectively. The warrant liability was estimated using the Black-Scholes pricing model with the following assumptions. September 30, 2024 December 31, 2023 Risk-free interest rate 3.58 % 3.89 % Expected volatility 84.85 % 76.30 % Expected life (years) 3.69 4.44 Expected dividend yield - - Total fair value $ 96,225 $ 126,649 The fair value of the warrants issued in the 2023 Equity Capital Raise was deemed to be a liability, due to certain contingent put features, and was determined using the Black-Scholes option pricing model, which was deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price. 2024 Equity Capital Raise On August 8, 2024, the Company entered into a securities purchase agreement with a purchaser pursuant to which the Company issued and sold to such purchaser, in a registered direct offering under the 2021 Form S-3 (the “2024 Equity Capital Raise”), an aggregate of 9,170,000 shares of the Company’s common stock, pre-funded warrants to purchase up to 3,557,273 shares of the Company’s common stock (the “Pre-Funded Warrants”), Series A common stock warrants to purchase up to 12,727,273 shares of the Company’s common stock (the “Series A Warrants”) and Series B common stock warrants to purchase up to 12,727,273 shares of the Company’s common stock (the “Series B Warrants” and, together with the Series A Warrants, the “Common Warrants” and, together with the shares of common stock offered in the 2024 Equity Capital Raise and the Pre-Funded Warrants, the “Securities”). The exercise prices of the Pre-Funded Warrants and the Common Warrants is $0.001 per share and $0.57 per share, respectively. H.C. Wainwright & Co. acted as the exclusive placement agent for the Company in the offering. The combined offering price for a share of common stock and accompanying Common Warrants was $0.55 and the combined offering price for a Pre-Funded Warrant and accompanying Common Warrants was $0.549. The net proceeds received by the Company for the issuance and sale of the Securities was $6.4 million, before deducting offering expenses of $0.1 million paid by the Company. In addition, the Company issued warrants to the placement agent to purchase an aggregate of 381,818 shares of Company common stock on substantially the same terms as the Series B Warrants at an exercise price of $0.6875 per share. The net proceeds above assumes the exercise of the Pre-Funded Warrants but excludes any proceeds arising from the exercise of the Common Warrants or the placement agent warrants. Common Stock Issued for EpiCypher License Agreement On March 12, 2024, the Company issued 129,132 shares of restricted common stock to EpiCypher, Inc. at a price of $0.97 per share as partial consideration for license rights in connection with a License Agreement between EpiCypher and Belgian Volition. Equity Distribution Agreement On May 20, 2022, the Company entered into an equity distribution agreement (the “2022 EDA”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, with an aggregate offering price of up to $25.0 million, from time to time through an “at the market” offering pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259783) effective November 8, 2021 (the “2021 Form S-3”) through Jefferies acting as the Company’s agent and/or principal. The Company is not obligated to sell any shares under the 2022 EDA. During the nine months ended September 30, 2024, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $605,221 under the 2022 EDA through the sale of 747,505 shares of its common stock. As of September 30, 2024, the Company has raised aggregate net proceeds (net of broker commissions and fees) of approximately $2.1 million under the 2022 EDA through the sale of 1,378,037 shares of its common stock.

Stock Based Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2024
Stock Based Compensation
Stock-based Compensation	Note 7 – Stock-Based Compensation a) (i) Common Stock Warrants The following table summarizes the changes in common stock warrants of the Company outstanding during the nine-month period ended September 30, 2024. Number of Warrants Weighted Average Exercise Price ($) Outstanding at December 31, 2023 862,500 3.050 Granted 3,557,273 0.001 Expired/Cancelled - - Outstanding at September 30, 2024 4,419,773 0.597 Exercisable at September 30, 2024 4,419,773 0.597 Below is a table summarizing the common stock warrants issued and outstanding as of September 30, 2024, which have an aggregate weighted average remaining contractual life of 0.60 years. The proceeds if exercised assume the warrants are exercised for cash. Number Outstanding Number Exercisable Exercise Price ($) Weighted Average Remaining Contractual Life (Years) Proceeds to Company if Exercised ($) 3,557,273 3,557,273 0.001 - 3,557 448,500 448,500 2.000 3.71 897,000 54,000 54,000 3.050 4.01 164,700 50,000 50,000 3.450 1.42 172,500 125,000 125,000 3.950 2.25 493,750 185,000 185,000 4.900 2.34 906,500 4,419,773 4,419,773 2,638,007 Stock-based compensation expense related to warrants of $5,238 and $25,447 was recorded in the nine months ended September 30, 2024 and September 30, 2023, respectively. Total remaining unrecognized compensation cost related to non-vested warrants is $nil. As of September 30, 2024, the total intrinsic value of warrants outstanding was $nil. a ) (ii) Warrants – Series A and Series B Common Stock Warrants The following table summarizes the changes in Series A and Series B common stock warrants of the Company outstanding during the nine-month period ended September 30, 2024. Number of Warrants Weighted Average Exercise Price ($) Outstanding at December 31, 2023 - - Granted 25,836,364 0.57 Exercised - - Expired/Cancelled - - Outstanding at September 30, 2024 25,836,364 0.57 Exercisable at September 30, 2024 - - Below is a table summarizing the Series A and Series B common stock warrants issued and outstanding as of September 30, 2024, which have a maximum aggregate weighted average remaining contractual life of 3.88 years (assuming that certain Company milestones set forth in the warrants are not achieved). The proceeds if exercised as reflected in the table below assume the warrants are exercised for cash. Description Number Outstanding Number Exercisable Exercise Price ($) Weighted Average Remaining Contractual Life (Years) Proceeds to Company if Exercised ($) Investor A Warrants 12,727,273 - 0.5700 2.36 7,254,546 Investor B Warrants 12,727,273 - 0.5700 5.36 7,254,546 Placement Agent Series B Warrants 381,818 - 0.6875 4.86 262,500 25,836,364 - 14,771,591 b) Options The following table summarizes the changes in options outstanding of the Company during the nine-month period ended September 30, 2024. Number of Options Weighted Average Exercise Price ($) Outstanding at December 31, 2023 4,699,569 3.87 Expired/Cancelled (36,821 ) 3.40 Outstanding at September 30, 2024 4,662,748 3.88 Exercisable at September 30, 2024 4,662,748 3.88 b ) Options (continued) Below is a table summarizing the options issued and outstanding as of September 30, 2024, all of which were issued pursuant to the Company’s 2011 Equity Incentive Plan (for option issuances prior to 2016) or the 2015 Plan (for option and RSU issuances commencing in 2016)and which have an aggregate weighted average remaining contractual life of 3.46 years. As of September 30, 2024, an aggregate of 9,700,000 shares of common stock were authorized for issuance under the 2015 Plan, of which 603,502 shares of common stock remained available for future issuance thereunder. At the Annual Meeting on July 2, 2024, the stockholders approved and adopted the Company’s 2024 Stock Incentive Plan (the “ 2024 Plan Number Outstanding Number Exercisable Exercise Price ($) Weighted Average Remaining Contractual Life (Years) Proceeds to Company if Exercised ($) 585,000 585,000 3.25 0.36 1,901,250 944,748 944,748 3.40 6.84 3,212,143 740,000 740,000 3.60 5.61 2,664,000 1,607,837 1,607,837 4.00 1.98 6,431,348 89,163 89,163 4.38 3.32 390,534 50,000 50,000 4.80 2.25 240,000 646,000 646,000 5.00 2.49 3,230,000 4,662,748 4,662,748 18,069,275 Stock-based compensation expense related to stock options of $nil and $287,013 was recorded in the nine months ended September 30, 2024 and September 30, 2023, respectively. Total remaining unrecognized compensation cost related to non-vested stock options is $nil. As of September 30, 2024, the total intrinsic value of stock options outstanding was $nil. c ) Restricted Stock Units Below is a table summarizing the RSUs issued and outstanding as of September 30, 2024, all of which were issued pursuant to the 2015 Plan. RSUs (#) Weighted Average Grant Date Fair Value Share Price ($) Outstanding at December 31, 2023 3,634,952 1.01 Granted 844,313 0.71 Vested/Settled (573,203 ) 1.40 Cancelled / Forfeited (677,213 ) 0.83 Outstanding at September 30, 2024 3,228,849 0.90 c ) Restricted Stock Units (continued) Below is a table summarizing the RSUs granted during the nine months ended September 30, 2024, all of which were issued pursuant to the 2015 Plan. The RSUs vest equally over periods stated on the dates noted, subject to the recipient’s continued service to the Company, and will result in the RSU compensation expense stated. On June 1, 2024, the Company granted 297,340 RSUs of common stock to certain directors and employees in exchange for their election to reduce their cash compensation for a period of three months for services provided to the Company. These RSUs will vest on May 1, 2025, subject to continued service by the recipient. On July 1, 2024, the Company granted 38,198 RSUs of common stock to an employee in exchange for the employee’s election to reduce their cash compensation for a period of three months for services provided to the Company. These RSUs will vest on June 1, 2025, subject to continued service by the recipient. On July 8, 2024, the Company granted 21,583 RSUs of common stock to a consultant in exchange for advisory services. These RSUs will vest on January 1, 2025, subject to continued service to the Company by the recipient. On September 1, 2024, the Company granted 343,192 RSUs of common stock to certain directors and employees in exchange for their election to reduce their cash compensation for a period of three months for services provided to the Company. These RSUs will vest on June 1, 2025, subject to continued service by the recipient. On September 30, 2024, the Company granted 15,000 RSUs to a non-employee director, vesting in three equal installments on the first, second and third anniversaries of the date of grant, subject to continued services by the recipient. Equity Incentive Plan RSUs Granted (#) Grant Date Vesting Period First Vesting Date Second Vesting Date Third Vesting Date RSU Expense ($) 2015 14,000 Feb 22, 2024 36 Months Feb 22, 2025 Feb 22, 2026 Feb 22, 2027 13,589 2015 115,000 May 23, 2024 36 Months May 23, 2025 May 23, 2026 May 23, 2027 85,389 2015 297,340 Jun 1, 2024 11 Months May 1, 2025 N/A N/A 209,832 2015 38,198 Jul 1, 2024 11 Months Jun 1, 2025 N/A N/A 23,645 2015 21,583 Jul 8, 2024 6 Months Jan 1, 2025 N/A N/A 13,209 2015 343,192 Sep 1, 2024 9 Months Jun 1, 2025 N/A N/A 247,098 2015 15,000 Sep 30, 2024 36 Months Sep 30, 2025 Sep 30, 2026 Sep 30, 2027 9,015 844,313 601,777 c ) Restricted Stock Units (continued) Below is a table summarizing the RSUs vested and settled during the nine months ended September 30, 2024, all of which were issued pursuant to the 2015 Plan. Equity Incentive Plan RSUs Vested (#) Vest Date Shares Issued (#) Shares Withheld for Taxes (#) 2015 21,582 Feb 8, 2024 21,582 - 2015 9,000 Mar 1, 2024 6,057 2,943 2015 44,217 Mar 27, 2024 40,530 3,687 2015 51,000 Apr 4, 2024 32,337 18,663 2015 50,000 May 1, 2024 34,496 15,504 2015 11,500 Jun 1, 2024 6,670 4,830 2015 14,962 Jun 15, 2024 11,684 3,278 2015 4,667 Jul 13, 2024 3,165 1,502 2015 29,000 Aug 15, 2024 21,291 7,709 2015 2,000 Sep 11, 2024 2,000 - 2015 2,500 Sep 21, 2024 2,500 - 2015 332,775 Sep 28, 2024 265,300 67,475 573,203 447,612 125,591 c ) Restricted Stock Units (continued) Below is a table summarizing the RSUs cancelled during the nine months ended September 30, 2024, all of which were originally issued pursuant to the 2015 Plan. Equity Incentive Plan RSUs (#) Cancellation Date Vesting Date RSUs Cancelled (#) 2015 8,000 Jan 16, 2024 Sep 28, 2024 8,000 2015 6,000 Jan 16, 2024 Oct 4, 2024 6,000 2015 8,000 Jan 16, 2024 Sep 28, 2025 8,000 2015 6,000 Jan 16, 2024 Oct 4, 2025 6,000 2015 8,000 Jan 16, 2024 Sep 28, 2026 8,000 2015 667 Feb 9, 2024 Jun 15, 2024 667 2015 667 Feb 9, 2024 Jun 15, 2025 667 2015 666 Feb 9, 2024 Jun 15, 2026 666 2015 1,775 Mar 25, 2024 Mar 27, 2024 1,775 2015 2,098 Mar 25, 2024 Jun 15, 2024 2,098 2015 2,667 May 17, 2024 Oct 4, 2024 2,667 2015 2,666 May 17, 2024 Oct 4, 2025 2,666 2015 1,000 May 17, 2024 Mar 27, 2025 1,000 2015 1,000 May 17, 2024 Mar 27, 2026 1,000 2015 3,334 May 17, 2024 Sep 28, 2024 3,334 2015 3,333 May 17, 2024 Sep 28, 2025 3,333 2015 3,333 May 17, 2024 Sep 28, 2026 3,333 2015 9,334 May 31, 2024 Sep 11, 2024 9,334 2015 9,333 May 31, 2024 Sep 11, 2025 9,333 2015 9,333 May 31, 2024 Sep 11, 2026 9,333 2015 3,333 Jul 12, 2024 Oct 4, 2024 3,333 2015 3,333 Jul 12, 2024 Oct 4, 2025 3,333 2015 5,666 Aug 4, 2024 Oct 4, 2025 5,666 2015 10,000 Aug 4, 2024 Sep 21, 2024 10,000 2015 5,667 Aug 4, 2024 Oct 4, 2024 5,667 2015 178,909 Aug 15, 2024 Sep 28, 2024 178,909 2015 178,894 Aug 15, 2024 Sep 28, 2025 178,894 2015 178,872 Aug 15, 2024 Sep 28, 2026 178,872 2015 8,000 Aug 31, 2024 Mar 27, 2025 8,000 2015 8,000 Aug 31, 2024 Mar 27, 2026 8,000 2015 4,667 Aug 31, 2024 Oct 4, 2024 4,667 2015 4,666 Aug 31, 2024 Oct 4, 2025 4,666 677,213 677,213 c ) Restricted Stock Units (continued) Below is a table summarizing the RSUs issued and outstanding as of September 30, 2024 and which have an aggregate weighted average remaining contractual life of 1.23 years. RSUs Outstanding (#) Weighted Average Grant Date Fair Value Share Price ($) Weighted Average Remaining Contractual Life (Years) 40,000 0.58 1.12 15,000 0.60 2.00 21,583 0.61 0.25 38,198 0.62 0.67 450,000 0.68 2.55 450,000 0.69 1.51 665,550 0.70 1.00 297,340 0.71 0.58 343,192 0.72 0.67 115,000 0.74 1.64 14,000 0.97 1.40 4,000 1.31 0.97 9,333 1.32 0.86 675,322 1.46 0.49 17,332 1.58 0.60 38,333 1.72 0.92 666 2.15 0.66 34,000 2.95 0.13 3,228,849 Stock-based compensation expense related to RSUs of $937,567 and $1,511,351 was recorded in the nine months ended September 30, 2024 and September 30, 2023, respectively. Total remaining unrecognized compensation cost related to non-vested RSUs is $1,031,071.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies
Commitments And Contingencies	Note 8 – Commitments and Contingencies a) Finance Lease Obligations The following is a schedule showing the future minimum lease payments under finance leases by years and the present value of the minimum payments as of September 30, 2024. 2024 - Remaining $ 14,983 2025 $ 59,934 2026 $ 59,934 2027 $ 59,934 2028 $ 59,933 Greater than 5 years $ 202,259 Total $ 456,977 Less: Amount representing interest $ (40,812 ) Present value of minimum lease payments $ 416,165 b) Operating Lease Right-of-Use Obligations Operating leases as of September 30, 2024, and December 31, 2023, consisted of the following: September 30, 2024 December 31, 2023 $ $ Operating right-of-use assets 635,857 549,504 Operating lease liabilities, current portion 190,099 199,323 Operating lease liabilities, long term 350,810 378,054 Total operating lease liabilities 540,909 577,377 Weighted average remaining lease (months) 47 33 Weighted average discount rate 3.70 % 3.02 % During the nine months ended September 30, 2024, cash paid for amounts included for the measurement of lease liabilities was $185,692 and the Company recorded operating lease expense of $167,465. b) Operating Lease Right-of-Use Obligations (continued) The following is a schedule showing the future minimum lease payments under operating leases by years and the present value of the minimum payments as of September 30, 2024. For the Nine Months Ending September 30, 2024 Amount $ 2024 - Remaining 61,552 2025 241,924 2026 225,368 2027 144,593 2028 44,059 Total 717,496 Less: imputed interest (50,391 ) Total Operating Lease Liabilities 667,105 The Company’s office space leases are short-term and the Company has elected under the short-term recognition exemption not to recognize them on the balance sheet. During the nine months ended September 30, 2024, the Company recognized $45,161 in short-term lease costs associated with office space leases. The annual payments remaining for short-term office leases were as follows: For the Nine Months Ending September 30, 2024 Amount $ 2024 - Remaining 27,481 2025 12,373 Total Operating Lease Liabilities 39,854 c) Grants Repayable As of September 30, 2024, the total grant balance repayable was $454,544 and the payments remaining were as follows: For the Nine Months Ending September 30, 2024 Amount $ 2024 - Remaining 27,857 2025 37,789 2026 45,545 2027 50,564 2028 54,073 Greater than 5 years 238,716 Total Grants Repayable 454,544 d) Long-Term Debt As of September 30, 2024, the total balance for long-term debt payable was $4,802,971 and the payments remaining were as follows: For the Nine Months Ending September 30, 2024 Amount $ 2024 - Remaining 551,774 2025 1,046,366 2026 813,844 2027 607,484 2028 2,536,778 Greater than 5 years 326,851 Total 5,883,097 Less: amount representing interest (1,080,126 ) Total Long-Term Debt 4,802,971 e) Collaborative Agreement Obligations In 2018, the Company entered into a research collaboration agreement with the University of Taiwan for a three-year research period for a cost to the Company of up to $2.55 million payable over such period. As of September 30, 2024, $510,000 is still to be paid by the Company under this agreement. As of September 30, 2024, $510,000 is due by the Company under this agreement. In 2022, the Company entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps ("NETs") in cancer patients with sepsis for a cost to the Company of $327,092. As of September 30, 2024, $327,092 is still to be paid by the Company under this agreement. As of September 30, 2024, $138,971 is due by the Company under this agreement. In July 2023, the Company entered into a research agreement with Xenetic Biosciences Inc and CLS Therapeutics Ltd to evaluate the anti-tumoral effects of Nu.Q ® In August 2023, the Company entered into a project research agreement with Guy’s and St Thomas’ NHS Foundation Trust to evaluate the practical clinical utility of the Nu.Q ® In January 2024, the Company entered into an agreement with the University Medical Centre Amsterdam (“UMC”). UMC will perform a retrospective study to evaluate the diagnostic potential of the Nu.Q ® e) Collaborative Agreement Obligations (continued) As of September 30, 2024, the total amount to be paid for future research and collaboration commitments was $1,232,263 and the payments remaining were as follows: Total Amount Remaining 2024 - Remaining 2025 $ $ $ National University of Taiwan 510,000 510,000 - MD Anderson Cancer Center 327,092 163,546 163,546 Guys and St Thomas 217,464 65,239 152,225 Xenetic Biosciences 81,447 26,142 55,305 UMC 96,260 48,058 48,202 Total Collaborative Obligations 1,232,263 812,985 419,278 f) Other Commitments Volition Germany As of September 30, 2024, $218 is payable under the royalty agreement with the founder of Volition’s former German subsidiary based on sales to date towards the Company’s aggregate minimum royalty obligation of $122,572. Volition America Effective February 10, 2024 the Company and Diagnostic Oncology CRO, LLC (“DXOCRO”) further amended and restated the August 2022 amended and restated Master Agreement by and between the Company and DXOCRO to expand the scope of DXOCRO’s consultant services provided thereunder (the “Second A&R Master Agreement”). The Second A&R Master Agreement requires DXOCRO to conduct a prospective optimization/range finding study of Volition’s Nu.Q ® VolitionRx On February 5, 2024, the Company entered into a 9-month loan agreement with First Insurance Funding for a maximum of $294,603 with fixed interest rate of 8.42%, maturing in November 2024. As of September 30, 2024, the maximum has been drawn down under this agreement and the principal balance payable was $65,467. The agreement is in relation to the directors and officers insurance policy. g) Legal Proceedings In the ordinary course of business, the Company may be subject to claims, counter-claims, lawsuits and other litigation of the type that generally arise from the conduct of its business. The Company knows of no legal proceedings which the Company believes will have a material adverse effect on its financial position. h) Commitments in Respect of Corporate Goals and Performance-Based Awards As of September 30, 2024, the Company has recognized total compensation expense of $1,396,638 of which $527,940 is in relation to RSUs from grants in 2022 that vested in 2023, $513,394 is in relation to RSUs from such grants that will vest in 2024, and $355,304 is in relation to RSUs from such grants that will vest in 2025. The Company has unrecognized compensation expense of $168,518 in relation to such RSUs, based on the outcomes related to the prescribed performance targets on the outstanding awards. Total Vesting Amortized Amortized Amortized Un-Amortized Award Year 2024 2023 2022 $ $ $ $ $ 527,940 2023 - 393,853 134,087 - 516,040 2024 188,187 260,119 65,088 2,646 521,176 2025 131,034 177,584 46,686 165,872 1,565,156 319,221 831,556 245,861 168,518 In September 2023, the Compensation Committee of the Board of Directors of the Company approved the granting of cash bonuses, payable upon achievement of various corporate goals focused around revenue, operations and regulatory, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries. Pursuant to the terms of the grants, conditional upon the achievement by December 31, 2023 and June 30, 2024 of specified corporate goals as set forth in the minutes of the Compensation Committee, as well as continued service by the award recipients to the Company, the Company at the sole discretion of the Chief Executive Officer and the Chief Financial Officer would pay a cash bonus to such award recipients. As of September 30, 2024, the Company has accrued compensation expense of $536,535 in relation to cash bonuses payable on the achievement of specified corporate goals based on the expected outcomes related to the prescribed performance targets. To the extent this is payable, this cash bonus compensation payment has currently been deferred indefinitely. As of September 30, 2024, the Company had recognized total compensation expense of $447,008. The Company has unrecognized compensation expense of $270,104 in relation to the RSUs from grants in 2023, of which $0 is in relation to RSUs that will vest in 2024, $115,517 in relation to RSUs that will vest in 2025, and $154,587 in relation to RSUs that will vest in 2026 based on the outcomes related to the prescribed performance targets on the outstanding awards. Total Vesting Amortized Amortized Un-Amortized Award Year 2024 2023 2024 $ $ $ $ 242,902 2024 148,132 94,770 - 237,936 2025 74,906 47,513 115,517 236,274 2026 49,984 31,703 154,587 717,112 273,022 173,986 270,104

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events
Subsequent Events	Note 9 – Subsequent Events Settlement of RSUs On October 4, 2024, 337,666 RSUs previously granted to various employees vested and resulted in the issuance of 272,242 shares of common stock. 65,424 shares of common stock were withheld for taxes and returned to the 2015 Plan. RSUs Granted Effective October 1, 2024, the Company granted RSUs of 33,503 shares of common stock under the Company’s 2015 Plan to an employee of the Company in exchange their valid election to reduce their cash compensation for a period of three months for services provided to the Company. These RSUs will vest on July 1, 2025, subject to continued service by the employee. Effective November 6, 2024, the Company granted aggregate RSUs of 400,000 shares of common stock under the Company’s 2015 Plan to a director of the Company and/or its subsidiaries in exchange for services provided to the Company and/or its subsidiaries. These RSUs vest over three years, with one-third vesting on each of November 6, 2025, November 6, 2026 and November 6, 2027, subject to continued service, and will result in total compensation expense of $240,800. Effective November 6, 2024, the Company granted aggregate RSUs of 1,000,000 shares of common stock under the Company’s 2024 Plan to a director in exchange for services provided to the Company. These RSUs vest in two equal installments following the achievement of a closing stock price target above $2.50 per share and above $5.00 per share, respectively, of the Company’s common stock for a minimum of thirty consecutive trading days prior to November 6, 2027 (but no earlier than November 2025), and also subject to time-based vesting in a single installment six months after the timely achievement of each stock price target, if at all, and subject to continued service. The estimated fair value of the RSUs that include a market vesting condition will be measured on the grant date using a Monte Carlo Simulation of a Geometric Brownian Motion stock path model and incorporating the probability of vesting occurring. The estimated fair value of these awards will be recognized over the derived service period (as determined by the valuation model), with such recognition occurring regardless of whether the market condition is met. Cancellation of Stock Options On November 4 2024, 25,000 vested stock options previously granted to an employee were cancelled and returned as authorized shares under the 2015 Plan on the expiration of the exercise period following the resignation of such employee. Long-Term Debt On October 29, 2024, the Company entered into a 4-year loan agreement with Namur Invest Preface for an amount of €577,975 with fixed interest rate of 7.00%, maturing September 2028. Appointment of Director and Non-Executive Chairman On November 6, 2024 the Board, pursuant to the Company’s bylaws, passed a resolution to increase the size of the Board to eight (8) members and appointed Mr. Timothy I. Still to fill the new vacancy on the Board and fill the role of Non-Executive Chairman effective as of November 6, 2024. Mr. Still will have an initial term expiring at the Company’s 2025 annual meeting of stockholders, subject to his future nomination by the Nominations and Governance Committee and election by the Company’s stockholders. In connection with his appointment, Mr. Still and the Company entered into an Independent Director Agreement, pursuant to which Mr. Still will continue to serve as a member of the Board subject to any necessary approval by the Company’s stockholders as required by applicable law and the Company’s governing documents. In exchange for his services, pursuant to the terms of the Independent Director Agreement Mr. Still shall receive (i) $30,000 per calendar quarter commencing November 6, 2024; (ii) $1,000 per day for any services performed as a member of a committee of the Company, if any, (iii) a grant of RSUs under the Company’s 2015 Stock Incentive Plan to receive an aggregate of four hundred thousand (400,000) shares of the Company’s common stock underlying the RSUs (as described above under the heading “RSUs Granted”). and (iv) a grant of RSUs under the Company’s 2024 Stock Incentive Plan to receive an aggregate of one million (1,000,000) shares of the Company’s common stock underlying the RSUs, (as described above under the heading “RSUs Granted”). The Independent Director Agreement provides that in the event that the Company undergoes a Change of Control (as defined below), the vesting of the RSUs in (iv) above shall be accelerated to fully-vest the rights to such RSUs provided that the purchase price per share of the Company’s common stock in such transaction exceeds $2.50 per share. “Change of Control” shall mean the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation. The Independent Director Agreement also provides that Mr. Still shall be awarded RSUs to receive three hundred thousand (300,000) shares of the Company’s common stock on an annual basis, the vesting of which will be subject to the timely achievement by the Company, or one of its affiliates, of certain corporate goals as determined by the Board or a designated committee in its absolute discretion and upon the terms and conditions set forth in the award agreement and, if applicable, the governing plan. The grant of these annual RSU awards shall be subject to availability of shares under the governing plan and be made concurrently with the grant of RSUs, on equivalent terms, to the other members of the Board.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and use of estimates	The accompanying unaudited condensed consolidated financial statements of VolitionRx Limited (the “Company” or “VolitionRx”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q of Regulation S-X. They do not include all the information and footnotes required by GAAP for complete financial statements. The December 31, 2023 consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the audited consolidated financial statements and accompanying notes thereto for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 25, 2024 (the “Annual Report”). The interim unaudited condensed consolidated financial statements should be read in conjunction with those audited consolidated financial statements included in the Annual Report. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The preparation of the Company's Condensed Consolidated Financial Statements requires management to make certain estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported and reported amounts of revenues and expenses. Such estimates include impairment of long-lived assets, accounts receivable, useful lives of intangible assets and property and equipment, fair values of stock-based awards, income taxes among others. These estimates and assumptions are based on management’s judgment. Estimates and underlying assumptions are reviewed on an ongoing basis. Changes in accounting estimates may be necessary if there are changes in the circumstances or experiences on which the estimate was based or as a result of new information. Changes in estimates, including those resulting from changes in the economic environment, are reflected in the period in which the change in estimate occurs.
Reclassifications	Certain reclassifications within operating expenses have been made to the prior period’s financial statements to conform to the current period financial statement presentation. There is no impact in total to the results of operations and cash flows in all periods presented.
Recently Issued Accounting Pronouncements	In November 2023, the Financial Accounting Standards Board (the “FASB” issued Accounting Standards Update (“ASU”) 2023-07, “ Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, “ Income Taxes (Topic 740): Improvements to Income Tax Disclosures The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to its condensed consolidated financial statements.
Fair Value Measurements	Pursuant to ASC 820, “ Fair Value Measurements and Disclosures,” Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The financial instruments of the Company consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, debt, and a warrant liability. These items are considered Level 1 due to their short-term nature and their market interest rates, except for the warrant liability, which is considered Level 2 and is recorded at fair value at the end of each reporting period. Included in the following table are the Company’s major categories of assets and liabilities measured at fair value on a recurring basis as of September 30, 2024. Fair Value Measurements at September 30, 2024 Description Level 1 Level 2 Level 3 Total $ $ $ $ Liabilities Warrant liability - 96,225 - 96,225 As of December 31, 2023, the warrant liability was $126,649. The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis for the nine months ended September 30, 2024. Warrant Liability Total $ Balance at December 31, 2023 126,649 Gain on change in fair value of warrant liability (30,424 ) Balance at September 30, 2024 96,225
Basic And Diluted Net Loss Per Share	The Company computes net loss per share in accordance with ASC 260, “ Earnings Per Share,”

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2024
Basis of Presentation and Summary of Significant Accounting Policies
Schedule Of assets and liabilities measured at fair value on a recurring basis	Fair Value Measurements at September 30, 2024 Description Level 1 Level 2 Level 3 Total $ $ $ $ Liabilities Warrant liability - 96,225 - 96,225
Schedule Of warrant liability measured at fair value	Warrant Liability Total $ Balance at December 31, 2023 126,649 Gain on change in fair value of warrant liability (30,424 ) Balance at September 30, 2024 96,225

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2024
Property and Equipment
Schedule Of Property And Equipment	September 30, 2024 December 31, 2023 Useful Life Cost $ Cost $ Computer hardware and software 3 years 751,488 724,534 Laboratory equipment 5 years 4,847,622 4,753,253 Office furniture and equipment 5 years 382,970 378,800 Buildings 30 years 2,132,927 2,113,031 Building improvements 5-15 years 1,690,268 1,610,016 Land Not amortized 133,715 132,468 Total property and equipment 9,938,990 9,712,102 Less accumulated depreciation 5,030,842 4,189,089 Total property and equipment, net 4,908,148 5,523,013

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2024
Intangible Assets
Schedule Of Intangible Assets	September 30, 2024 December 31, 2023 Cost $ Cost $ Patents 1,148,969 1,130,936 Licenses 296,353 - Total Patents and Licenses 1,445,322 1,130,936 Less accumulated amortization 1,110,013 1,107,050 Total patents and Licenses, net 335,309 23,886
Schedule Of Annual Estimated Amortization	2024 $ 5,187 2025 $ 20,748 2026 $ 20,748 2027 $ 20,748 2028 $ 20,748 Greater than 5 years $ 247,130 Total Intangible Assets $ 335,309

Common Stock (Tables)

Common Stock (Tables)	9 Months Ended
	Sep. 30, 2024
Common Stock
Summary of RSUs vested and settled during period	Equity Incentive Plan RSUs Vested (#) Vest Date Shares Issued (#) Shares Withheld for Taxes (#) 2015 21,582 Feb 8, 2024 21,582 - 2015 9,000 Mar 1, 2024 6,057 2,943 2015 44,217 Mar 27, 2024 40,530 3,687 2015 51,000 Apr 4, 2024 32,337 18,663 2015 50,000 May 1, 2024 34,496 15,504 2015 11,500 Jun 1, 2024 6,670 4,830 2015 14,962 Jun 15, 2024 11,684 3,278 2015 4,667 Jul 13, 2024 3,165 1,502 2015 29,000 Aug 15, 2024 21,291 7,709 2015 2,000 Sep 11, 2024 2,000 - 2015 2,500 Sep 21, 2024 2,500 - 2015 332,775 Sep 28, 2024 265,300 67,475 573,203 447,612 125,591
Schedule of fair value of the warrants	September 30, 2024 December 31, 2023 Risk-free interest rate 3.58 % 3.89 % Expected volatility 84.85 % 76.30 % Expected life (years) 3.69 4.44 Expected dividend yield - - Total fair value $ 96,225 $ 126,649

Stock Based Compensation (Table

Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Stock Based Compensation
Summary Of Changes In Warrants Outstanding	Number of Warrants Weighted Average Exercise Price ($) Outstanding at December 31, 2023 862,500 3.050 Granted 3,557,273 0.001 Expired/Cancelled - - Outstanding at September 30, 2024 4,419,773 0.597 Exercisable at September 30, 2024 4,419,773 0.597 Number of Warrants Weighted Average Exercise Price ($) Outstanding at December 31, 2023 - - Granted 25,836,364 0.57 Exercised - - Expired/Cancelled - - Outstanding at September 30, 2024 25,836,364 0.57 Exercisable at September 30, 2024 - -
Summarizing The Warrants Issued And Outstanding	Number Outstanding Number Exercisable Exercise Price ($) Weighted Average Remaining Contractual Life (Years) Proceeds to Company if Exercised ($) 3,557,273 3,557,273 0.001 - 3,557 448,500 448,500 2.000 3.71 897,000 54,000 54,000 3.050 4.01 164,700 50,000 50,000 3.450 1.42 172,500 125,000 125,000 3.950 2.25 493,750 185,000 185,000 4.900 2.34 906,500 4,419,773 4,419,773 2,638,007 Number Outstanding Number Exercisable Exercise Price ($) Weighted Average Remaining Contractual Life (Years) Proceeds to Company if Exercised ($) 585,000 585,000 3.25 0.36 1,901,250 944,748 944,748 3.40 6.84 3,212,143 740,000 740,000 3.60 5.61 2,664,000 1,607,837 1,607,837 4.00 1.98 6,431,348 89,163 89,163 4.38 3.32 390,534 50,000 50,000 4.80 2.25 240,000 646,000 646,000 5.00 2.49 3,230,000 4,662,748 4,662,748 18,069,275
Summarizes The Changes In Options Outstanding	Number of Options Weighted Average Exercise Price ($) Outstanding at December 31, 2023 4,699,569 3.87 Expired/Cancelled (36,821 ) 3.40 Outstanding at September 30, 2024 4,662,748 3.88 Exercisable at September 30, 2024 4,662,748 3.88
Summarizes The warrants are exercised for cash	Description Number Outstanding Number Exercisable Exercise Price ($) Weighted Average Remaining Contractual Life (Years) Proceeds to Company if Exercised ($) Investor A Warrants 12,727,273 - 0.5700 2.36 7,254,546 Investor B Warrants 12,727,273 - 0.5700 5.36 7,254,546 Placement Agent Series B Warrants 381,818 - 0.6875 4.86 262,500 25,836,364 - 14,771,591
Summarizing The Rsus Issued And Outstanding	RSUs (#) Weighted Average Grant Date Fair Value Share Price ($) Outstanding at December 31, 2023 3,634,952 1.01 Granted 844,313 0.71 Vested/Settled (573,203 ) 1.40 Cancelled / Forfeited (677,213 ) 0.83 Outstanding at September 30, 2024 3,228,849 0.90
Schedule of RSUs granted during period	Equity Incentive Plan RSUs Granted (#) Grant Date Vesting Period First Vesting Date Second Vesting Date Third Vesting Date RSU Expense ($) 2015 14,000 Feb 22, 2024 36 Months Feb 22, 2025 Feb 22, 2026 Feb 22, 2027 13,589 2015 115,000 May 23, 2024 36 Months May 23, 2025 May 23, 2026 May 23, 2027 85,389 2015 297,340 Jun 1, 2024 11 Months May 1, 2025 N/A N/A 209,832 2015 38,198 Jul 1, 2024 11 Months Jun 1, 2025 N/A N/A 23,645 2015 21,583 Jul 8, 2024 6 Months Jan 1, 2025 N/A N/A 13,209 2015 343,192 Sep 1, 2024 9 Months Jun 1, 2025 N/A N/A 247,098 2015 15,000 Sep 30, 2024 36 Months Sep 30, 2025 Sep 30, 2026 Sep 30, 2027 9,015 844,313 601,777
Schedule of RSUs vested and settled during period	Equity Incentive Plan RSUs Vested (#) Vest Date Shares Issued (#) Shares Withheld for Taxes (#) 2015 21,582 Feb 8, 2024 21,582 - 2015 9,000 Mar 1, 2024 6,057 2,943 2015 44,217 Mar 27, 2024 40,530 3,687 2015 51,000 Apr 4, 2024 32,337 18,663 2015 50,000 May 1, 2024 34,496 15,504 2015 11,500 Jun 1, 2024 6,670 4,830 2015 14,962 Jun 15, 2024 11,684 3,278 2015 4,667 Jul 13, 2024 3,165 1,502 2015 29,000 Aug 15, 2024 21,291 7,709 2015 2,000 Sep 11, 2024 2,000 - 2015 2,500 Sep 21, 2024 2,500 - 2015 332,775 Sep 28, 2024 265,300 67,475 573,203 447,612 125,591
Schedule of RSUs cancelled	Equity Incentive Plan RSUs (#) Cancellation Date Vesting Date RSUs Cancelled (#) 2015 8,000 Jan 16, 2024 Sep 28, 2024 8,000 2015 6,000 Jan 16, 2024 Oct 4, 2024 6,000 2015 8,000 Jan 16, 2024 Sep 28, 2025 8,000 2015 6,000 Jan 16, 2024 Oct 4, 2025 6,000 2015 8,000 Jan 16, 2024 Sep 28, 2026 8,000 2015 667 Feb 9, 2024 Jun 15, 2024 667 2015 667 Feb 9, 2024 Jun 15, 2025 667 2015 666 Feb 9, 2024 Jun 15, 2026 666 2015 1,775 Mar 25, 2024 Mar 27, 2024 1,775 2015 2,098 Mar 25, 2024 Jun 15, 2024 2,098 2015 2,667 May 17, 2024 Oct 4, 2024 2,667 2015 2,666 May 17, 2024 Oct 4, 2025 2,666 2015 1,000 May 17, 2024 Mar 27, 2025 1,000 2015 1,000 May 17, 2024 Mar 27, 2026 1,000 2015 3,334 May 17, 2024 Sep 28, 2024 3,334 2015 3,333 May 17, 2024 Sep 28, 2025 3,333 2015 3,333 May 17, 2024 Sep 28, 2026 3,333 2015 9,334 May 31, 2024 Sep 11, 2024 9,334 2015 9,333 May 31, 2024 Sep 11, 2025 9,333 2015 9,333 May 31, 2024 Sep 11, 2026 9,333 2015 3,333 Jul 12, 2024 Oct 4, 2024 3,333 2015 3,333 Jul 12, 2024 Oct 4, 2025 3,333 2015 5,666 Aug 4, 2024 Oct 4, 2025 5,666 2015 10,000 Aug 4, 2024 Sep 21, 2024 10,000 2015 5,667 Aug 4, 2024 Oct 4, 2024 5,667 2015 178,909 Aug 15, 2024 Sep 28, 2024 178,909 2015 178,894 Aug 15, 2024 Sep 28, 2025 178,894 2015 178,872 Aug 15, 2024 Sep 28, 2026 178,872 2015 8,000 Aug 31, 2024 Mar 27, 2025 8,000 2015 8,000 Aug 31, 2024 Mar 27, 2026 8,000 2015 4,667 Aug 31, 2024 Oct 4, 2024 4,667 2015 4,666 Aug 31, 2024 Oct 4, 2025 4,666 677,213 677,213
Schedule of RSUs issued and outstanding and average contractual life	RSUs Outstanding (#) Weighted Average Grant Date Fair Value Share Price ($) Weighted Average Remaining Contractual Life (Years) 40,000 0.58 1.12 15,000 0.60 2.00 21,583 0.61 0.25 38,198 0.62 0.67 450,000 0.68 2.55 450,000 0.69 1.51 665,550 0.70 1.00 297,340 0.71 0.58 343,192 0.72 0.67 115,000 0.74 1.64 14,000 0.97 1.40 4,000 1.31 0.97 9,333 1.32 0.86 675,322 1.46 0.49 17,332 1.58 0.60 38,333 1.72 0.92 666 2.15 0.66 34,000 2.95 0.13 3,228,849

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies
Schedule of future minimum lease payments under financing leases	2024 - Remaining $ 14,983 2025 $ 59,934 2026 $ 59,934 2027 $ 59,934 2028 $ 59,933 Greater than 5 years $ 202,259 Total $ 456,977 Less: Amount representing interest $ (40,812 ) Present value of minimum lease payments $ 416,165
Schedule of operating lease	September 30, 2024 December 31, 2023 $ $ Operating right-of-use assets 635,857 549,504 Operating lease liabilities, current portion 190,099 199,323 Operating lease liabilities, long term 350,810 378,054 Total operating lease liabilities 540,909 577,377 Weighted average remaining lease (months) 47 33 Weighted average discount rate 3.70 % 3.02 %
Schedule Of Future Minimum Lease Payments Under Operating Leases	For the Nine Months Ending September 30, 2024 Amount $ 2024 - Remaining 61,552 2025 241,924 2026 225,368 2027 144,593 2028 44,059 Total 717,496 Less: imputed interest (50,391 ) Total Operating Lease Liabilities 667,105
Schedule Of Recognized In Short-term Lease Costs	For the Nine Months Ending September 30, 2024 Amount $ 2024 - Remaining 27,481 2025 12,373 Total Operating Lease Liabilities 39,854
Schedule Of Grants Repayable	For the Nine Months Ending September 30, 2024 Amount $ 2024 - Remaining 27,857 2025 37,789 2026 45,545 2027 50,564 2028 54,073 Greater than 5 years 238,716 Total Grants Repayable 454,544
Schedule Of Long-term Debt Payable	For the Nine Months Ending September 30, 2024 Amount $ 2024 - Remaining 551,774 2025 1,046,366 2026 813,844 2027 607,484 2028 2,536,778 Greater than 5 years 326,851 Total 5,883,097 Less: amount representing interest (1,080,126 ) Total Long-Term Debt 4,802,971
Schedule of annual payments Of Collaborative Agreement Obligations	Total Amount Remaining 2024 - Remaining 2025 $ $ $ National University of Taiwan 510,000 510,000 - MD Anderson Cancer Center 327,092 163,546 163,546 Guys and St Thomas 217,464 65,239 152,225 Xenetic Biosciences 81,447 26,142 55,305 UMC 96,260 48,058 48,202 Total Collaborative Obligations 1,232,263 812,985 419,278
Schedule of commitments in respect of corporate goals and performance based awards	Total Vesting Amortized Amortized Amortized Un-Amortized Award Year 2024 2023 2022 $ $ $ $ $ 527,940 2023 - 393,853 134,087 - 516,040 2024 188,187 260,119 65,088 2,646 521,176 2025 131,034 177,584 46,686 165,872 1,565,156 319,221 831,556 245,861 168,518 Total Vesting Amortized Amortized Un-Amortized Award Year 2024 2023 2024 $ $ $ $ 242,902 2024 148,132 94,770 - 237,936 2025 74,906 47,513 115,517 236,274 2026 49,984 31,703 154,587 717,112 273,022 173,986 270,104

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Warrant liability	$ 96,225	$ 126,649
Fair Value Inputs Level 1 [Member]
Warrant liability	0
Fair Value Inputs Level 2 [Member]
Warrant liability	96,225
Fair Value Inputs Level 3 [Member]
Warrant liability	$ 0

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies (Details 1)	9 Months Ended
	Sep. 30, 2024 USD ($)
Basis of Presentation and Summary of Significant Accounting Policies
Warrant Liability beginning balance	$ 126,649
Gain on change in fair value of warrant liability	(30,424)
Warrant Liability ending balance	$ 96,225

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Basis of Presentation and Summary of Significant Accounting Policies
Warrant Liability	$ 96,225	$ 126,649
Potentially Dilutive Securities Excluded From The Computation Of Eps	38,147,734

Liquidity and Going Concern A_2

Liquidity and Going Concern Assessment (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Accumulated deficit	$ (223,750,970)						$ (223,750,970)		$ (202,576,507)
Cash and cash equivalents	5,414,146			$ 10,808,747			5,414,146	$ 10,808,747	$ 20,729,983	$ 10,867,050
Cash flows from operating activities							(20,461,849)	$ (24,510,735)
Net Loss	(5,868,578)	$ (7,060,175)	$ (8,472,005)	$ (8,453,188)	$ (9,551,277)	$ (8,872,909)
Liquidity and Going Concern Assessment [Member]
Accumulated deficit	(223,800,000)						(223,800,000)
Cash and cash equivalents	$ 5,400,000						5,400,000
Cash flows from operating activities							20,500,000
Net Loss							$ (21,400,000)

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Total property and equipment	$ 9,938,990	$ 9,712,102
Less accumulated depreciation	5,030,842	4,189,089
Total property and equipment net	4,908,148	5,523,013
Computer Hardware And Software [Member]
Total property and equipment	$ 751,488	724,534
Estimated useful life	3 years
Laboratory Equipment [Member]
Total property and equipment	$ 4,847,622	4,753,253
Estimated useful life	5 years
Office Furniture and Equipment [Member]
Total property and equipment	$ 382,970	378,800
Estimated useful life	5 years
Buildings [Member]
Total property and equipment	$ 2,132,927	2,113,031
Estimated useful life	30 years
Building Improvements [Member]
Total property and equipment	$ 1,690,268	1,610,016
Building Improvements [Member] | Minimum [Member]
Estimated useful life	5 years
Building Improvements [Member] | Maximum [Member]
Estimated useful life	15 years
Land [Member]
Total property and equipment	$ 133,715	$ 132,468

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Property and Equipment
Depreciation Expense	$ 815,824	$ 792,232

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Total Patents and Licenses	$ 1,445,322	$ 1,130,936
Less accumulated amortization	1,110,013	1,107,050
Total patents and Licenses, net	335,309	23,886
Patents [Member]
Total Patents and Licenses	1,148,969	1,130,936
Licenses [Member]
Total Patents and Licenses	$ 296,353	$ 0

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Intangible Assets
2024	$ 5,187
2025	20,748
2026	20,748
2027	20,748
2028	20,748
Greater than 5 years	247,130
Total Intangible Assets	$ 335,309	$ 23,886

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Amortization Expense	$ (6,742)	$ 63,715
Patents And Intellectual Property [Member] | Minimum [Member]
Amortization Of Patents On Straight Line Basis	8 years
Patents And Intellectual Property [Member] | Maximum [Member]
Amortization Of Patents On Straight Line Basis	20 years

Common Stock (Details)

Common Stock (Details)	9 Months Ended
	Sep. 30, 2024 USD ($) shares
Equity Incentive RSU	573,203
Incentive RSU Issued	447,612
RSUs Held for Taxes | $	$ 125,591
Equity Incentive Plan Eight [Member]
Equity Incentive RSU	4,667
Incentive RSU Issued	3,165
RSUs Held for Taxes | $	$ 1,502
Incentive Plan	2015
Incentive Vest Date	Jul. 13, 2024
Equity Incentive Plan Nine [Member]
Equity Incentive RSU	29,000
Incentive RSU Issued	21,291
RSUs Held for Taxes | $	$ 7,709
Incentive Plan	2015
Incentive Vest Date	Aug. 15, 2024
Equity Incentive Plan One [Member]
Equity Incentive RSU	21,582
Incentive RSU Issued	21,582
RSUs Held for Taxes | $	$ 0
Incentive Plan	2015
Incentive Vest Date	Feb. 08, 2024
Equity Incentive Plan Two [Member]
Equity Incentive RSU	9,000
Incentive RSU Issued	6,057
RSUs Held for Taxes | $	$ 2,943
Incentive Plan	2015
Incentive Vest Date	Mar. 01, 2024
Equity Incentive Plan Three [Member]
Equity Incentive RSU	44,217
Incentive RSU Issued	40,530
RSUs Held for Taxes | $	$ 3,687
Incentive Plan	2015
Incentive Vest Date	Mar. 27, 2024
Equity Incentive Plan Ten [Member]
Equity Incentive RSU	2,000
Incentive RSU Issued	2,000
RSUs Held for Taxes | $	$ 0
Incentive Plan	2015
Incentive Vest Date	Sep. 11, 2024
Equity Incentive Plan Eleven [Member]
Equity Incentive RSU	2,500
Incentive RSU Issued	2,500
RSUs Held for Taxes | $	$ 0
Incentive Plan	2015
Incentive Vest Date	Sep. 21, 2024
Equity Incentive Plan Four [Member]
Equity Incentive RSU	51,000
Incentive RSU Issued	32,337
RSUs Held for Taxes | $	$ 18,663
Incentive Plan	2015
Incentive Vest Date	Apr. 04, 2024
Equity Incentive Plan Five [Member]
Equity Incentive RSU	50,000
Incentive RSU Issued	34,496
RSUs Held for Taxes | $	$ 15,504
Incentive Plan	2015
Incentive Vest Date	May 01, 2024
Equity Incentive Plan Six [Member]
Equity Incentive RSU	11,500
Incentive RSU Issued	6,670
RSUs Held for Taxes | $	$ 4,830
Incentive Plan	2015
Incentive Vest Date	Jun. 01, 2024
Equity Incentive Plan Seven [Member]
Equity Incentive RSU	14,962
Incentive RSU Issued	11,684
RSUs Held for Taxes | $	$ 3,278
Incentive Plan	2015
Incentive Vest Date	Jun. 15, 2024
Equity Incentive Plan Twelve [Member]
Equity Incentive RSU	332,775
Incentive RSU Issued	265,300
RSUs Held for Taxes | $	$ 67,475
Incentive Plan	2015
Incentive Vest Date	Sep. 28, 2024

Common Stock (Details 1)

Common Stock (Details 1) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Common Stock
Risk-free interest rate	3.58%	3.89%
Expected volatility	84.85%	76.30%
Expected term (years)	3 years 8 months 8 days	4 years 5 months 8 days
Expected dividend yield	0%	0%
Total fair value	$ 96,225	$ 126,649

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)			1 Months Ended			9 Months Ended	12 Months Ended
	Aug. 08, 2024	Mar. 12, 2024	Apr. 16, 2024	Jun. 30, 2023	May 20, 2022	Sep. 30, 2024	Dec. 31, 2023
Common stock price per share						$ 0.001
Common stock, shares authorized						175,000,000
Common stock, shares issued						92,392,570	81,898,321
Common stock, shares outstanding						92,392,570	81,898,321
Total fair value						$ 96,225	$ 126,649
Underwriting Agreement [Member]
Total fair value						$ 96,225	$ 126,649
Warrants issued to purchase shares of common stock				448,500
Exercise price				$ 2
EpiCypher License Agreement [Member]
Common stock price per share		$ 0.97
Issuance of restricted common stock		129,132
Equity Distribution Agreement [Member]
Common stock shares sold						747,505
Aggeregate share of common stock offering price					$ 25,000,000
Aggregate net proceeds						$ 605,221
2022 EDA [Member]
Common stock shares sold						1,378,037
Commissions and fee						$ 2,100,000
2015 [Member]
Vested stock options			36,821
Securities Purchase Agreement [Member]
Pre-Funded Warrants	3,557,273
Warrants issued to purchase common shares	381,818
Exercise price	$ 0.001
Offering price	$ 0.55
Offering expenses	$ 100,000
Common stock shares sold	9,170,000
Securities Purchase Agreement [Member] | Series A Warrants [Member]
Pre-Funded Warrants	12,727,273
Exercise price	$ 0.57
Offering price	$ 0.549
Securities Purchase Agreement [Member] | Series B Warrants [Member]
Pre-Funded Warrants	12,727,273
Exercise price	$ 0.6875

StockBased Compensation (Detail

StockBased Compensation (Details) - Warrants [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Number of warrants Outstanding beginning balance | shares	862,500
Granted | shares	3,557,273
Number of warrants outstanding ending balance | shares	4,419,773
Number of Warrants Exercisable | shares	4,419,773
Weighted Average Exercise Price Outstanding balance	$ 3.050
Weighted Average Exercise Price, Granted	0.001
Weighted Average Exercise Price, Expired/Cancelled	0
Weighted Average Exercise Price, ending balance	0.597
Weighted Average Exercise Price, exercisable	$ 0.597

StockBased Compensation (Deta_2

StockBased Compensation (Details 1)	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Warrants [Member]
Number Exercisable	4,419,773
Proceeds to Company if Exercised | $	$ 2,638,007
Number Outstanding	4,419,773
Warrant One [Member]
Number Exercisable	3,557,273
Exercise Price | $ / shares	$ 0.001
Proceeds to Company if Exercised | $	$ 3,557
Weighted Average Remaining Contractual Life (Years)	0 years
Number Outstanding	3,557,273
Warrant Two [Member]
Number Exercisable	448,500
Exercise Price | $ / shares	$ 2
Proceeds to Company if Exercised | $	$ 897,000
Weighted Average Remaining Contractual Life (Years)	3 years 8 months 15 days
Number Outstanding	448,500
Warrant Three [Member]
Number Exercisable	54,000
Exercise Price | $ / shares	$ 3.050
Proceeds to Company if Exercised | $	$ 164,700
Weighted Average Remaining Contractual Life (Years)	4 years 3 days
Number Outstanding	54,000
Warrants Four [Member]
Number Exercisable	50,000
Exercise Price | $ / shares	$ 3.450
Proceeds to Company if Exercised | $	$ 172,500
Weighted Average Remaining Contractual Life (Years)	1 year 5 months 1 day
Number Outstanding	50,000
Warrants Five [Member]
Number Exercisable	125,000
Exercise Price | $ / shares	$ 3.950
Proceeds to Company if Exercised | $	$ 493,750
Weighted Average Remaining Contractual Life (Years)	2 years 3 months
Number Outstanding	125,000
Warrants Six [Member]
Number Exercisable	185,000
Exercise Price | $ / shares	$ 4.900
Proceeds to Company if Exercised | $	$ 906,500
Weighted Average Remaining Contractual Life (Years)	2 years 4 months 2 days
Number Outstanding	185,000

StockBased Compensation (Deta_3

StockBased Compensation (Details 2) - Warrants Series A and Series B [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Granted | shares	25,836,364
Number of warrants outstanding ending balance | shares	25,836,364
Weighted Average Exercise Price Outstanding balance	$ 0
Weighted Average Exercise Price, Granted	0.57
Weighted Average Exercise Price, Expired/Cancelled	0
Weighted Average Exercise Price, ending balance	0.57
Weighted Average Exercise Price, exercisable	$ 0

StockBased Compensation (Deta_4

StockBased Compensation (Details 3)	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Warrants Series A and Series B [Member]
Proceeds to Company if Exercised | $	$ 14,771,591
Number Outstanding | shares	25,836,364
Investor A Warrants [Member]
Exercise Price | $ / shares	$ 0.5700
Proceeds to Company if Exercised | $	$ 7,254,546
Weighted Average Remaining Contractual Life (Years)	2 years 4 months 9 days
Number Outstanding | shares	12,727,273
Placement Agent Series B Warrants [Member]
Exercise Price | $ / shares	$ 0.6875
Proceeds to Company if Exercised | $	$ 262,500
Weighted Average Remaining Contractual Life (Years)	4 years 10 months 9 days
Number Outstanding | shares	381,818
Investor B Warrants [Member]
Exercise Price | $ / shares	$ 0.5700
Proceeds to Company if Exercised | $	$ 7,254,546
Weighted Average Remaining Contractual Life (Years)	5 years 4 months 9 days
Number Outstanding | shares	12,727,273

StockBased Compensation (Deta_5

StockBased Compensation (Details 4) - Option [Member]	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Number of options outstanding beginning balance | shares	4,699,569
Number of options, Expired/Cancelled | $	$ (36,821)
Number of option outstanding ending balance | shares	4,662,748
Number of options, exercisable | shares	4,662,748
Weighted Average Exercise Price Outstanding balance	$ 3.87
Weighted Average Exercise Price expires/cancelled	3.40
Weighted Average Exercise Price ending balance	3.88
Weighted Average Exercise Price exercisable balance	$ 3.88

StockBased Compensation (Deta_6

StockBased Compensation (Details 5)	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Option Six [Member]
Number Exercisable, shares	50,000
Exercise Price | $ / shares	$ 4.80
Weighted Average Remaining Contractual Life (years)	2 years 3 months
Proceeds to Company if Exercised | $	$ 240,000
Number Outstanding, shares	50,000
Option Seven [Member]
Number Exercisable, shares	646,000
Exercise Price | $ / shares	$ 5
Weighted Average Remaining Contractual Life (years)	2 years 5 months 26 days
Proceeds to Company if Exercised | $	$ 3,230,000
Number Outstanding, shares	646,000
Options One [Member]
Number Exercisable, shares	585,000
Exercise Price | $ / shares	$ 3.25
Weighted Average Remaining Contractual Life (years)	4 months 9 days
Proceeds to Company if Exercised | $	$ 1,901,250
Number Outstanding, shares	585,000
Option Two [Member]
Number Exercisable, shares	944,748
Exercise Price | $ / shares	$ 3.40
Weighted Average Remaining Contractual Life (years)	6 years 10 months 2 days
Proceeds to Company if Exercised | $	$ 3,212,143
Number Outstanding, shares	944,748
Option Three [Member]
Number Exercisable, shares	740,000
Exercise Price | $ / shares	$ 3.60
Weighted Average Remaining Contractual Life (years)	5 years 7 months 9 days
Proceeds to Company if Exercised | $	$ 2,664,000
Number Outstanding, shares	740,000
Option Four [Member]
Number Exercisable, shares	1,607,837
Exercise Price | $ / shares	$ 4
Weighted Average Remaining Contractual Life (years)	1 year 11 months 23 days
Proceeds to Company if Exercised | $	$ 6,431,348
Number Outstanding, shares	1,607,837
Option Five [Member]
Number Exercisable, shares	89,163
Exercise Price | $ / shares	$ 4.38
Weighted Average Remaining Contractual Life (years)	3 years 3 months 25 days
Proceeds to Company if Exercised | $	$ 390,534
Number Outstanding, shares	89,163
Total Option [Member]
Number Exercisable, shares	4,662,748
Proceeds to Company if Exercised | $	$ 18,069,275
Number Outstanding, shares	4,662,748

StockBased Compensation (Deta_7

StockBased Compensation (Details 6) - Stock Options [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Number Of Rsus Outstanding Begining Balance shares | shares	3,634,952
Granted | shares	844,313
Vested/Settled | shares	(573,203)
Cancelled / Forfeited | shares	(677,213)
Number Of Rsus Outstanding ending Balance | shares	3,228,849
Share Price Beginning Balance shares | $ / shares	$ 1.01
Share Price Granted | $ / shares	0.71
Share Price Vested/Settled | $ / shares	1.40
Share Price Cancelled / Forfeited | $ / shares	0.83
Share Price ending Balance | $ / shares	$ 0.90

StockBased Compensation (Deta_8

StockBased Compensation (Details 7)	9 Months Ended
	Sep. 30, 2024 USD ($) shares
RSU Expense | $	$ 601,777
Compensation Expense RSUs | shares	844,313
Compensation Expense One [Member]
RSU Expense | $	$ 13,589
Compensation Expense RSUs | shares	14,000
Equity Incentive Plan	2015
Compensation Expense grant date	Feb. 22, 2024
Compensation Expense Vesting Period	36 Months
First Vesting date	Feb. 22, 2025
Second vesting date	Feb. 22, 2026
Third vesting date	Feb. 22, 2027
Compensation Expense Two [Member]
RSU Expense | $	$ 85,389
Compensation Expense RSUs | shares	115,000
Equity Incentive Plan	2015
Compensation Expense grant date	May 23, 2024
Compensation Expense Vesting Period	36 Months
First Vesting date	May 23, 2025
Second vesting date	May 23, 2026
Third vesting date	May 23, 2027
Compensation Expense Three [Member]
RSU Expense | $	$ 209,832
Compensation Expense RSUs | shares	297,340
Equity Incentive Plan	2015
Compensation Expense grant date	Jun. 01, 2024
Compensation Expense Vesting Period	11 Months
First Vesting date	May 01, 2025
Compensation Expense Four [Member]
RSU Expense | $	$ 23,645
Compensation Expense RSUs | shares	38,198
Equity Incentive Plan	2015
Compensation Expense grant date	Jul. 01, 2024
Compensation Expense Vesting Period	11 Months
First Vesting date	Jun. 01, 2025
Compensation Expense Five [Member]
RSU Expense | $	$ 13,209
Compensation Expense RSUs | shares	21,583
Equity Incentive Plan	2015
Compensation Expense grant date	Jul. 08, 2024
Compensation Expense Vesting Period	6 Months
First Vesting date	Jan. 01, 2025
Compensation Expense Six [Member]
RSU Expense | $	$ 247,098
Compensation Expense RSUs | shares	343,192
Equity Incentive Plan	2015
Compensation Expense grant date	Sep. 01, 2024
Compensation Expense Vesting Period	9 Months
First Vesting date	Jun. 01, 2025
Compensation Expense Seven [Member]
RSU Expense | $	$ 9,015
Compensation Expense RSUs | shares	15,000
Equity Incentive Plan	2015
Compensation Expense grant date	Sep. 30, 2024
Compensation Expense Vesting Period	36 Months
First Vesting date	Sep. 30, 2025
Second vesting date	Sep. 30, 2026
Third vesting date	Sep. 30, 2027

StockBased Compensation (Deta_9

StockBased Compensation (Details 8)	9 Months Ended
	Sep. 30, 2024 USD ($) shares
Equity Incentive RSU	573,203
Incentive RSU Issued	447,612
RSUs Held for Taxes | $	$ 125,591
Equity Incentive Plan Eight [Member]
Incentive Plan	2015
Equity Incentive RSU	4,667
Incentive Vest Date	Jul. 13, 2024
Incentive RSU Issued	3,165
RSUs Held for Taxes | $	$ 1,502
Equity Incentive Plan Nine [Member]
Incentive Plan	2015
Equity Incentive RSU	29,000
Incentive Vest Date	Aug. 15, 2024
Incentive RSU Issued	21,291
RSUs Held for Taxes | $	$ 7,709
Equity Incentive Plan One [Member]
Incentive Plan	2015
Equity Incentive RSU	21,582
Incentive Vest Date	Feb. 08, 2024
Incentive RSU Issued	21,582
RSUs Held for Taxes | $	$ 0
Equity Incentive Plan Two [Member]
Incentive Plan	2015
Equity Incentive RSU	9,000
Incentive Vest Date	Mar. 01, 2024
Incentive RSU Issued	6,057
RSUs Held for Taxes | $	$ 2,943
Equity Incentive Plan Three [Member]
Incentive Plan	2015
Equity Incentive RSU	44,217
Incentive Vest Date	Mar. 27, 2024
Incentive RSU Issued	40,530
RSUs Held for Taxes | $	$ 3,687
Equity Incentive Plan Ten [Member]
Incentive Plan	2015
Equity Incentive RSU	2,000
Incentive Vest Date	Sep. 11, 2024
Incentive RSU Issued	2,000
RSUs Held for Taxes | $	$ 0
Equity Incentive Plan Eleven [Member]
Incentive Plan	2015
Equity Incentive RSU	2,500
Incentive Vest Date	Sep. 21, 2024
Incentive RSU Issued	2,500
RSUs Held for Taxes | $	$ 0
Equity Incentive Plan Four [Member]
Incentive Plan	2015
Equity Incentive RSU	51,000
Incentive Vest Date	Apr. 04, 2024
Incentive RSU Issued	32,337
RSUs Held for Taxes | $	$ 18,663
Equity Incentive Plan Five [Member]
Incentive Plan	2015
Equity Incentive RSU	50,000
Incentive Vest Date	May 01, 2024
Incentive RSU Issued	34,496
RSUs Held for Taxes | $	$ 15,504
Equity Incentive Plan Six [Member]
Incentive Plan	2015
Equity Incentive RSU	11,500
Incentive Vest Date	Jun. 01, 2024
Incentive RSU Issued	6,670
RSUs Held for Taxes | $	$ 4,830
Equity Incentive Plan Seven [Member]
Incentive Plan	2015
Equity Incentive RSU	14,962
Incentive Vest Date	Jun. 15, 2024
Incentive RSU Issued	11,684
RSUs Held for Taxes | $	$ 3,278
Equity Incentive Plan Twelve [Member]
Incentive Plan	2015
Equity Incentive RSU	332,775
Incentive Vest Date	Sep. 28, 2024
Incentive RSU Issued	265,300
RSUs Held for Taxes | $	$ 67,475

StockBased Compensation (Det_10

StockBased Compensation (Details 9)	9 Months Ended
	Sep. 30, 2024 shares
Incentive RSUs Cancelled	677,213
Equity Incentive RSU	573,203
Equity Incentive RSU	677,213
RSUs Cancelled Plan One [Member]
Incentive RSUs Cancelled	8,000
Equity Incentive Plan	2015
Equity Incentive RSU	8,000
Incentive Cancellation Date	Jan. 16, 2024
Incentive Vest Date	Sep. 28, 2024
RSUs Cancelled Plan Two [Member]
Incentive RSUs Cancelled	6,000
Equity Incentive Plan	2015
Equity Incentive RSU	6,000
Incentive Cancellation Date	Jan. 16, 2024
Incentive Vest Date	Oct. 04, 2024
RSUs Cancelled Plan Three [Member]
Incentive RSUs Cancelled	8,000
Equity Incentive Plan	2015
Equity Incentive RSU	8,000
Incentive Cancellation Date	Jan. 16, 2024
Incentive Vest Date	Sep. 28, 2025
RSUs Cancelled Plan Four [Member]
Incentive RSUs Cancelled	6,000
Equity Incentive Plan	2015
Equity Incentive RSU	6,000
Incentive Cancellation Date	Jan. 16, 2024
Incentive Vest Date	Oct. 04, 2025
RSUs Cancelled Plan Five [Member]
Incentive RSUs Cancelled	8,000
Equity Incentive Plan	2015
Equity Incentive RSU	8,000
Incentive Cancellation Date	Jan. 16, 2024
Incentive Vest Date	Sep. 28, 2026
RSUs Cancelled Plan Six [Member]
Incentive RSUs Cancelled	667
Equity Incentive Plan	2015
Equity Incentive RSU	667
Incentive Cancellation Date	Feb. 09, 2024
Incentive Vest Date	Jun. 15, 2024
RSUs Cancelled Plan Seven [Member]
Incentive RSUs Cancelled	667
Equity Incentive Plan	2015
Equity Incentive RSU	667
Incentive Cancellation Date	Feb. 09, 2024
Incentive Vest Date	Jun. 15, 2025
RSUs Cancelled Plan Eight [Member]
Incentive RSUs Cancelled	666
Equity Incentive Plan	2015
Equity Incentive RSU	666
Incentive Cancellation Date	Feb. 09, 2024
Incentive Vest Date	Jun. 15, 2026
RSUs Cancelled Plan Nine [Member]
Incentive RSUs Cancelled	1,775
Equity Incentive Plan	2015
Equity Incentive RSU	1,775
Incentive Cancellation Date	Mar. 25, 2024
Incentive Vest Date	Mar. 27, 2024
RSUs Cancelled Plan Ten [Member]
Incentive RSUs Cancelled	2,098
Equity Incentive Plan	2015
Equity Incentive RSU	2,098
Incentive Cancellation Date	Mar. 25, 2024
Incentive Vest Date	Jun. 15, 2024
RSUs Cancelled Plan Twenty Nine [Member]
Incentive RSUs Cancelled	8,000
Equity Incentive Plan	2015
Equity Incentive RSU	8,000
Incentive Cancellation Date	Aug. 31, 2024
Incentive Vest Date	Mar. 27, 2025
RSUs Cancelled Plan Thirty [Member]
Incentive RSUs Cancelled	8,000
Equity Incentive Plan	2015
Equity Incentive RSU	8,000
Incentive Cancellation Date	Aug. 31, 2024
Incentive Vest Date	Mar. 27, 2026
RSUs Cancelled Plan Thirty One [Member]
Incentive RSUs Cancelled	4,667
Equity Incentive Plan	2015
Equity Incentive RSU	4,667
Incentive Cancellation Date	Aug. 31, 2024
Incentive Vest Date	Oct. 04, 2024
RSUs Cancelled Plan Thirty Two [Member]
Incentive RSUs Cancelled	4,666
Equity Incentive Plan	2015
Equity Incentive RSU	4,666
Incentive Cancellation Date	Aug. 31, 2024
Incentive Vest Date	Oct. 04, 2025
RSUs Cancelled Plan Eleven [Member]
Incentive RSUs Cancelled	2,667
Equity Incentive Plan	2015
Equity Incentive RSU	2,667
Incentive Cancellation Date	May 17, 2024
Incentive Vest Date	Oct. 04, 2024
RSUs Cancelled Plan Twelve [Member]
Incentive RSUs Cancelled	2,666
Equity Incentive Plan	2015
Equity Incentive RSU	2,666
Incentive Cancellation Date	May 17, 2024
Incentive Vest Date	Oct. 04, 2025
RSUs Cancelled Plan Thirteen [Member]
Incentive RSUs Cancelled	1,000
Equity Incentive Plan	2015
Equity Incentive RSU	1,000
Incentive Cancellation Date	May 17, 2024
Incentive Vest Date	Mar. 27, 2025
RSUs Cancelled Plan Fourteen [Member]
Incentive RSUs Cancelled	1,000
Equity Incentive Plan	2015
Equity Incentive RSU	1,000
Incentive Cancellation Date	May 17, 2024
Incentive Vest Date	Mar. 27, 2026
RSUs Cancelled Plan Fifteen [Member]
Incentive RSUs Cancelled	3,334
Equity Incentive Plan	2015
Equity Incentive RSU	3,334
Incentive Cancellation Date	May 17, 2024
Incentive Vest Date	Sep. 28, 2024
RSUs Cancelled Plan Sixteen [Member]
Incentive RSUs Cancelled	3,333
Equity Incentive Plan	2015
Equity Incentive RSU	3,333
Incentive Cancellation Date	May 17, 2024
Incentive Vest Date	Sep. 28, 2025
RSUs Cancelled Plan Seventeen [Member]
Incentive RSUs Cancelled	3,333
Equity Incentive Plan	2015
Equity Incentive RSU	3,333
Incentive Cancellation Date	May 17, 2024
Incentive Vest Date	Sep. 28, 2026
RSUs Cancelled Plan Eighteen [Member]
Incentive RSUs Cancelled	9,334
Equity Incentive Plan	2015
Equity Incentive RSU	9,334
Incentive Cancellation Date	May 31, 2024
Incentive Vest Date	Sep. 11, 2024
RSUs Cancelled Plan Nineteen [Member]
Incentive RSUs Cancelled	9,333
Equity Incentive Plan	2015
Equity Incentive RSU	9,333
Incentive Cancellation Date	May 31, 2024
Incentive Vest Date	Sep. 11, 2025
RSUs Cancelled Plan Twenty [Member]
Incentive RSUs Cancelled	9,333
Equity Incentive Plan	2015
Equity Incentive RSU	9,333
Incentive Cancellation Date	May 31, 2024
Incentive Vest Date	Sep. 11, 2026
RSUs Cancelled Plan Twenty One [Member]
Incentive RSUs Cancelled	3,333
Equity Incentive Plan	2015
Equity Incentive RSU	3,333
Incentive Cancellation Date	Jul. 12, 2024
Incentive Vest Date	Oct. 04, 2024
RSUs Cancelled Plan Twenty Two [Member]
Incentive RSUs Cancelled	3,333
Equity Incentive Plan	2015
Equity Incentive RSU	3,333
Incentive Cancellation Date	Jul. 12, 2024
Incentive Vest Date	Oct. 04, 2025
RSUs Cancelled Plan Twenty Three [Member]
Incentive RSUs Cancelled	5,666
Equity Incentive Plan	2015
Equity Incentive RSU	5,666
Incentive Cancellation Date	Aug. 04, 2024
Incentive Vest Date	Oct. 04, 2025
RSUs Cancelled Plan Twenty Four [Member]
Incentive RSUs Cancelled	10,000
Equity Incentive Plan	2015
Equity Incentive RSU	10,000
Incentive Cancellation Date	Aug. 04, 2024
Incentive Vest Date	Sep. 21, 2024
RSUs Cancelled Plan Twenty Five [Member]
Incentive RSUs Cancelled	5,667
Equity Incentive Plan	2015
Equity Incentive RSU	5,667
Incentive Cancellation Date	Aug. 04, 2024
Incentive Vest Date	Oct. 04, 2024
RSUs Cancelled Plan Twenty Six [Member]
Incentive RSUs Cancelled	178,909
Equity Incentive Plan	2015
Equity Incentive RSU	178,909
Incentive Cancellation Date	Aug. 15, 2024
Incentive Vest Date	Sep. 28, 2024
RSUs Cancelled Plan Twenty Seven [Member]
Incentive RSUs Cancelled	178,894
Equity Incentive Plan	2015
Equity Incentive RSU	178,894
Incentive Cancellation Date	Aug. 15, 2024
Incentive Vest Date	Sep. 28, 2025
RSUs Cancelled Plan Twenty Eight [Member]
Incentive RSUs Cancelled	178,872
Equity Incentive Plan	2015
Equity Incentive RSU	178,872
Incentive Cancellation Date	Aug. 15, 2024
Incentive Vest Date	Sep. 28, 2026

StockBased Compensation (Det_11

StockBased Compensation (Details 10)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Option Ten [Member]
Number Of Stock Outstanding Balance	115,000
Share Price | $ / shares	$ 0.74
Weighted Average Remaining Contractual Life (years)	1 year 7 months 20 days
Options One [Member]
Number Of Stock Outstanding Balance	40,000
Share Price | $ / shares	$ 0.58
Weighted Average Remaining Contractual Life (years)	1 year 1 month 13 days
Option Two [Member]
Number Of Stock Outstanding Balance	15,000
Share Price | $ / shares	$ 0.60
Weighted Average Remaining Contractual Life (years)	2 years
Option Three [Member]
Number Of Stock Outstanding Balance	21,583
Share Price | $ / shares	$ 0.61
Weighted Average Remaining Contractual Life (years)	3 months
Option Four [Member]
Number Of Stock Outstanding Balance	38,198
Share Price | $ / shares	$ 0.62
Weighted Average Remaining Contractual Life (years)	8 months 1 day
Option Five [Member]
Number Of Stock Outstanding Balance	450,000
Share Price | $ / shares	$ 0.68
Weighted Average Remaining Contractual Life (years)	2 years 6 months 18 days
Total Option [Member]
Number Of Stock Outstanding Balance	3,228,849
Option Six [Member]
Number Of Stock Outstanding Balance	450,000
Share Price | $ / shares	$ 0.69
Weighted Average Remaining Contractual Life (years)	1 year 6 months 3 days
Option Seven [Member]
Number Of Stock Outstanding Balance	665,550
Share Price | $ / shares	$ 0.70
Weighted Average Remaining Contractual Life (years)	1 year
Option Eight [Member]
Number Of Stock Outstanding Balance	297,340
Share Price | $ / shares	$ 0.71
Weighted Average Remaining Contractual Life (years)	6 months 29 days
Option Nine [Member]
Number Of Stock Outstanding Balance	343,192
Share Price | $ / shares	$ 0.72
Weighted Average Remaining Contractual Life (years)	8 months 1 day
Option Eleven [Member]
Number Of Stock Outstanding Balance	14,000
Share Price | $ / shares	$ 0.97
Weighted Average Remaining Contractual Life (years)	1 year 4 months 24 days
Option Twelve [Member]
Number Of Stock Outstanding Balance	4,000
Share Price | $ / shares	$ 1.31
Weighted Average Remaining Contractual Life (years)	11 months 19 days
Option Thirteen [Member]
Number Of Stock Outstanding Balance	9,333
Share Price | $ / shares	$ 1.32
Weighted Average Remaining Contractual Life (years)	10 months 9 days
Option Fourteen [Member]
Number Of Stock Outstanding Balance	675,322
Share Price | $ / shares	$ 1.46
Weighted Average Remaining Contractual Life (years)	5 months 26 days
Option Fifteen [Member]
Number Of Stock Outstanding Balance	17,332
Share Price | $ / shares	$ 1.58
Weighted Average Remaining Contractual Life (years)	7 months 6 days
Option Sixteen [Member]
Number Of Stock Outstanding Balance	38,333
Share Price | $ / shares	$ 1.72
Weighted Average Remaining Contractual Life (years)	11 months 1 day
Option Seventeen [Member]
Number Of Stock Outstanding Balance	666
Share Price | $ / shares	$ 2.15
Weighted Average Remaining Contractual Life (years)	7 months 28 days
Option Eighteen [Member]
Number Of Stock Outstanding Balance	34,000
Share Price | $ / shares	$ 2.95
Weighted Average Remaining Contractual Life (years)	1 month 17 days

StockBased Compensation (Det_12

StockBased Compensation (Details Narrative) - USD ($)				1 Months Ended	3 Months Ended						9 Months Ended
	Sep. 02, 2024	Jul. 08, 2024	Jul. 02, 2024	Sep. 30, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-based Payment Arrangement, Noncash Expense					$ 323,539	$ 208,046	$ 411,220	$ 537,980	$ 592,174	$ 693,657
Restricted Stock Units (RSUs) [Member]
Weighted Average Remaining Contractual Life											1 year 2 months 23 days
Granted shares	343,192										297,340
Number of shares granted to employee			38,198
Number of shares granted to consultant		21,583
Number of shares granted to third party				15,000
Share-based Payment Arrangement, Noncash Expense											$ 937,567	$ 1,511,351
Remaining unrecognized compensation cost related to non-vested RSUs				$ 1,031,071	$ 1,031,071						1,031,071
Option [Member]
Share-based Payment Arrangement, Noncash Expense											$ 287,013	287,013
Option [Member] | 2015 Equity Incentive Plan [Member]
Weighted Average Remaining Contractual Life											3 years 5 months 15 days
Common Stock, Shares Authorized				9,700,000	9,700,000						9,700,000
Common Stock Shares Reserved For Future Issuance				603,502	603,502						603,502
Option [Member] | 2024 Stock Incentive Plan [Member]
Common Stock, Shares Authorized				7,500,000	7,500,000						7,500,000
Warrants [Member]
Weighted Average Remaining Contractual Life											7 months 6 days
Share-based Payment Arrangement, Noncash Expense											$ 5,238	$ 25,447
Warrants Series A and Series B [Member]
Weighted Average Remaining Contractual Life											3 years 10 months 17 days

Commitments and Contingencies_2

Commitments and Contingencies (Details) - Finance Lease Obligations [Member]	Sep. 30, 2024 USD ($)
2024 - remaining	$ 14,983
2025	59,934
2026	59,934
2027	59,934
2028	59,933
Greater than 5 years	202,259
Total	456,977
Less: Amount representing interest	(40,812)
Present value of minimum lease payments	$ 416,165

Commitments and Contingencies_3

Commitments and Contingencies (Details 1) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Operating right-of-use assets	$ 635,857	$ 549,504
Operating lease liabilities, current portion	219,060	199,323
Operating lease liabilities, long term	448,045	378,054
Operating Lease Right of Use Obligations [Member]
Operating right-of-use assets	$ 635,857	$ 549,504
Weighted average remaining lease (months)	47 months	33 months
Weighted average discount rate	3.70%	3.02%
Operating lease liabilities, current portion	$ 190,099	$ 199,323
Operating lease liabilities, long term	350,810	378,054
Total operating lease liabilities	$ 540,909	$ 577,377

Commitments and Contingencies_4

Commitments and Contingencies (Details 2)	Sep. 30, 2024 USD ($)
Less: imputed interest	$ (1,080,126)
Operating Lease Right of Use Obligations [Member]
2024 - Remaining	61,552
2025	241,924
2026	225,368
2027	144,593
2028	44,059
Total	717,496
Less: imputed interest	(50,391)
Total Operating Lease Liabilities	$ 667,105

Commitments and Contingencies_5

Commitments and Contingencies (Details 3)	Sep. 30, 2024 USD ($)
Commitments and Contingencies
2024 - Remaining	$ 27,481
2025	12,373
Total Operating Lease Liabilities	$ 39,854

Commitments and Contingencies_6

Commitments and Contingencies (Details 4)	Sep. 30, 2024 USD ($)
Total Grants Repayable	$ 454,544
Grants Repayable [Member]
2024 - Remaining	27,857
2025	37,789
2026	45,545
2027	50,564
2028	54,073
Greater than 5 years	238,716
Total Grants Repayable	$ 454,544

Commitments and Contingencies_7

Commitments and Contingencies (Details 5)	Sep. 30, 2024 USD ($)
Commitments and Contingencies
2024 - Remaining	$ 551,774
2025	1,046,366
2026	813,844
2027	607,484
2028	2,536,778
Greater than 5 years	326,851
Total	5,883,097
Less: imputed interest	(1,080,126)
Total Long-Term Debt	$ 4,802,971

Commitments and Contingencies_8

Commitments and Contingencies (Details 6)	Sep. 30, 2024 USD ($)
Total Amount Remaining	$ 1,232,263
2025	419,278
2024 - Remaining	812,985
National Universty of Taiwan
Total Amount Remaining	510,000
2025	0
2024 - Remaining	510,000
MD Anderson Cancer Center
Total Amount Remaining	327,092
2025	163,546
2024 - Remaining	163,546
Guys and St Thomas
Total Amount Remaining	217,464
2025	152,225
2024 - Remaining	65,239
Xentic Bioscience
Total Amount Remaining	81,447
2025	55,305
2024 - Remaining	26,142
UMC
Total Amount Remaining	96,260
2025	48,202
2024 - Remaining	$ 48,058

Commitments and Contingencies_9

Commitments and Contingencies (Details 7) - Restricted stock option	9 Months Ended
	Sep. 30, 2024 USD ($)
Outstanding Award 3
Outstanding award	$ 527,940
Amortized of outstanding award 2024	0
Amortized of outstanding award 2023	393,853
Amortized of outstanding award 2022	$ 134,087
Vesting period	2023
Unamortized of outstanding award	$ 0
Outstanding Award 4
Outstanding award	516,040
Amortized of outstanding award 2024	188,187
Amortized of outstanding award 2023	260,119
Amortized of outstanding award 2022	65,088
Unamortized of outstanding award	$ 2,646
Vesting period	2024
Outstanding Award 5
Outstanding award	$ 521,176
Amortized of outstanding award 2024	131,034
Amortized of outstanding award 2023	177,584
Amortized of outstanding award 2022	46,686
Unamortized of outstanding award	$ 165,872
Vesting period	2025
Total Member
Outstanding award	$ 1,565,156
Amortized of outstanding award 2024	319,221
Amortized of outstanding award 2023	831,556
Amortized of outstanding award 2022	245,861
Unamortized of outstanding award	$ 168,518

Commitments and Contingencie_10

Commitments and Contingencies (Details 8) - Restricted Stock Options Vested [Member]	9 Months Ended
	Sep. 30, 2024 USD ($)
Total Member
Outstanding award	$ 717,112
Amortized of outstanding award 2024	273,022
Amortized of outstanding award 2023	173,986
Unamortized of outstanding award	270,104
Outstanding Award 1
Outstanding award	$ 242,902
Vesting period	2024
Amortized of outstanding award 2024	$ 148,132
Amortized of outstanding award 2023	94,770
Unamortized of outstanding award	0
Outstanding Award 2
Outstanding award	$ 237,936
Vesting period	2025
Amortized of outstanding award 2024	$ 74,906
Amortized of outstanding award 2023	47,513
Unamortized of outstanding award	115,517
Outstanding Award 3
Outstanding award	$ 236,274
Vesting period	2026
Amortized of outstanding award 2024	$ 49,984
Amortized of outstanding award 2023	31,703
Unamortized of outstanding award	$ 154,587

Commitments and Contingencie_11

Commitments and Contingencies (Details Narrative) - USD ($)			9 Months Ended
	Feb. 05, 2024	Nov. 03, 2020	Sep. 30, 2024
Payments For Future Research And Collobration			$ 1,232,263
Total Grants Repayable			454,544
Principal balance payable			65,467
Aggerate Amount Payable, Description		under this agreement will be completed by the end of the third quarter of 2024 at a total additional cost to the Company of up to $0.7 million
Loan agreement, Description	9-month loan agreement with First Insurance Funding for a maximum of $294,603 with fixed interest rate of 8.42%, maturing in November 2024
Total Long-Term Debt			4,802,971
Amount payable for services rendered			138,971
Amount may be payable by Company in future periods for services rendered			0
Accrued compensation expense			536,535
Recognized total compensation expense			447,008
RSU 2023 [Member]
Unrecognized compensation expense			270,104
RSU 2024 [Member]
Unrecognized compensation expense			0
RSU 2025 [Member]
Unrecognized compensation expense			115,517
RSU 2026 [Member]
Unrecognized compensation expense			154,587
Two Thousand Twenty Two [Member] | Univercity Of Texas MD [Member]
Collaborative Obligations Amount Due			138,971
Additional Cost Of Company			327,092
Cost			327,092
August Two Thousand Twenty Three [Member] | Guy's and St Thomas' NHS Foundation Trust [Member]
Collaborative Obligations Amount Due			0
Additional Cost Of Company			217,464
Cost			217,464
July Thirty One Thousand Twenty Three [Member] | Xenetic Biosciences Inc and CLS Therapeutics [Member]
Collaborative Obligations Amount Due			26,142
Additional Cost Of Company			81,447
Cost			107,589
January TwoThousand Twenty Four [Member] | University Medical Centre Amsterdam[Member]
Collaborative Obligations Amount Due			48,106
Additional Cost Of Company			96,260
Cost			96,260
Managing Director's Agreement [Member]
Payment under the royalty agreement			218
Royalty Payment			122,572
Clinical Study Research Agreement [Member] | In 2018 [Member] | University of Taiwan [Member]
Collaborative Obligations Amount Due			510,000
Collaborative Obligations Amount			$ 2,550,000
Lease Agreement Expire Period			three-year
Cost			$ 510,000
Restricted Stock Units (RSUs) [Member]
Recognized total compensation expense			1,396,638
RSU Vested in 2024			513,394
RSU Vested in 2023			527,940
RSU Vested in 2025			355,304
Unrecognized compensation expense			168,518
Operating Lease Right of Use Obligations [Member]
Payment Of Lease Liabilities			185,692
Operating Lease Expense			167,465
Short Term Lease Costs			$ 45,161

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)					1 Months Ended	3 Months Ended
	Nov. 06, 2024 USD ($) $ / shares shares	Nov. 04, 2024 shares	Oct. 04, 2024 shares	Oct. 01, 2024 shares	Oct. 29, 2024 EUR (€)	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)
Compensation expense | $						$ 323,539	$ 208,046	$ 411,220	$ 537,980	$ 592,174	$ 693,657
Subsequent Event [Member]
Vested stock options granted cancelled		25,000
Common stock, shares withheld for taxes			65,424
Warrants issued to purchase			272,242
RSUs, vested			337,666
RSUs, granted	1,000,000
Subsequent Event [Member] | Minimum [Member]
Closing stock price | $ / shares	$ 2.50
Subsequent Event [Member] | Maximum [Member]
Closing stock price | $ / shares	$ 5
Subsequent Event [Member] | Independent Director Agreement [Member]
Description of agreement	(i) $30,000 per calendar quarter commencing November 6, 2024; (ii) $1,000 per day for any services performed as a member of a committee of the Company, if any, (iii) a grant of RSUs under the Company’s 2015 Stock Incentive Plan to receive an aggregate of four hundred thousand (400,000) shares of the Company’s common stock underlying the RSUs (as described above under the heading “RSUs Granted”). and (iv) a grant of RSUs under the Company’s 2024 Stock Incentive Plan to receive an aggregate of one million (1,000,000) shares of the Company’s common stock underlying the RSUs, (as described above under the heading “RSUs Granted”). The Independent Director Agreement provides that in the event that the Company undergoes a Change of Control (as defined below), the vesting of the RSUs in (iv) above shall be accelerated to fully-vest the rights to such RSUs provided that the purchase price per share of the Company’s common stock in such transaction exceeds $2.50 per share
Total voting power	50%
RSUs awarded of common stock	300,000
Subsequent Event [Member] | Loan agreement [Member]
Principal amount | €					€ 577,975
Interest rate					7%
Period of agreement					4 years
Subsequent Event [Member] | July 1, 2024 [Member]
RSUs, vested				33,503
Subsequent Event [Member] | July 8, 2024 [Member]
RSUs, granted	400,000
Compensation expense | $	$ 240,800